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Background: Venous ulceration is a common and costly health-care issue worldwide, with poor healing
rates greatly affecting patient quality of life. Compression bandaging has been shown to improve healing
rates and reduce recurrence, but does not address the underlying cause, which is often superficial venous
reflux. Surgical correction of the reflux reduces ulcer recurrence; however, the effect of early endovenous
ablation of superficial venous reflux on ulcer healing is unclear.
Objectives: To determine the clinical effectiveness and cost-effectiveness of compression therapy with
early endovenous ablation of superficial venous reflux compared with compression therapy with deferred
endovenous ablation in patients with venous ulceration.
Design: A pragmatic, two-arm, multicentre, parallel-group, open randomised controlled trial with a health
economic evaluation.
Setting: Secondary care vascular centres in England.
Participants: Patients aged ≥ 18 years with a venous leg ulcer of between 6 weeks’ and 6 months’
duration and an ankle–brachial pressure index of ≥ 0.8 who could tolerate compression and were deemed
suitable for endovenous ablation of superficial venous reflux.
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Interventions: Participants were randomised 1 : 1 to either early ablation (compression therapy and
superficial endovenous ablation within 2 weeks of randomisation) or deferred ablation (compression
therapy followed by endovenous ablation once the ulcer had healed).
Main outcome measures: The primary outcome measure was time from randomisation to ulcer healing,
confirmed by blinded assessment. Secondary outcomes included 24-week ulcer healing rates, ulcer-free
time, clinical success (in addition to quality of life), costs and quality-adjusted life-years (QALYs). All analyses
were performed on an intention-to-treat basis.
Results: A total of 450 participants were recruited (224 to early and 226 to deferred superficial endovenous
ablation). Baseline characteristics were similar between the two groups. Time to ulcer healing was shorter in
participants randomised to early superficial endovenous ablation than in those randomised to deferred ablation
[hazard ratio 1.38, 95% confidence interval (CI) 1.13 to 1.68; p = 0.001]. Median time to ulcer healing was
56 (95% CI 49 to 66) days in the early ablation group and 82 (95% CI 69 to 92) days in the deferred ablation
group. The ulcer healing rate at 24 weeks was 85.6% in the early ablation group, compared with 76.3% in
the deferred ablation group. Median ulcer-free time was 306 [interquartile range (IQR) 240–328] days in the
early ablation group and 278 (IQR 175–324) days in the deferred endovenous ablation group (p = 0.002).
The most common complications of superficial endovenous ablation were pain and deep-vein thrombosis.
Differences in repeated measures of Aberdeen Varicose Vein Questionnaire scores (p < 0.001), EuroQol-5
Dimensions index values (p = 0.03) and Short Form questionnaire-36 items body pain (p = 0.05) over the
follow-up period were observed, in favour of early ablation. The mean difference in total costs between the
early ablation and deferred ablation groups was £163 [standard error (SE) £318; p = 0.607]; however, there
was a substantial and statistically significant gain in QALY over 1 year [mean difference between groups 0.041
(SE 0.017) QALYs; p = 0.017]. The incremental cost-effectiveness ratio of early ablation at 1 year was £3976
per QALY, with a high probability (89%) of being more cost-effective than deferred ablation at conventional
UK decision-making thresholds (currently £20,000 per QALY). Sensitivity analyses using alternative statistical
models give qualitatively similar results.
Limitations: Only 7% of screened patients were recruited, treatment regimens varied significantly and
technical success was assessed only in the early ablation group.
Conclusions: Early endovenous ablation of superficial venous reflux, in addition to compression therapy
and wound dressings, reduces the time to healing of venous leg ulcers, increases ulcer-free time and is
highly likely to be cost-effective.
Future work: Longer-term follow-up is ongoing and will determine if early ablation will affect recurrence
rates in the medium and long term.
Trial registration: Current Controlled Trials ISRCTN02335796.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 23, No. 24.
See the NIHR Journals Library website for further project information.
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Plain English summary
Venous leg ulcers are open wounds occurring on the legs of patients with venous disease. They arecommon, painful and distressing and reduce patient quality of life. Leg ulcers often result from
valves in the leg veins not working properly. The valves normally force blood back up towards the heart;
however, blood can flow backwards (reflux) when valves do not work properly, and this can cause swelling
and ulceration. Compression therapy (wrapping bandages around the legs) has been shown to help ulcers
heal, but it does not treat the underlying reflux problem with the veins. Newer, less invasive, techniques
(known as endovenous ablation) have taken over from surgery to correct venous reflux and are more
acceptable to patients as they can be performed quickly under local anaesthetic.
The aim of the trial was to find out if treating patients with leg ulcers by early endovenous ablation
(within 2 weeks) and standard compression therapy can increase ulcer healing compared with standard
compression therapy and delayed endovenous ablation once the ulcer has healed.
In total, 450 people agreed to take part in this study and were treated in 20 hospitals across England.
Participants were randomly allocated to either early or delayed endovenous ablation and followed up for
12 months.
The trial found that treating the veins early resulted in quicker ulcer healing than delaying treatment
until the ulcer had healed. The trial also showed that participants had more time without an ulcer if the
treatment was performed early rather than after ulcer healing. No safety issues with early intervention
were identified.
There is some evidence that quality of life was better in the early treatment group and that people in this
group had less body pain. Treating ulcers early appears likely to be more cost-effective (i.e. a better use of
NHS resources) than delayed treatment.
Future work will focus on collecting longer-term follow-up data to find out if early endovenous ablation
also reduces the chances of the ulcer coming back.
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Scientific summary
Background
Venous ulceration is a common and costly health problem worldwide, with poor healing rates affecting
patient quality of life and health service costs. Compression bandaging has been shown to improve healing
rates and reduce recurrence but does not address the underlying causes of venous hypertension (e.g.
superficial venous reflux). In addition, patient concordance with compression is often poor. Traditionally,
varicose vein surgery has been used to treat superficial venous reflux, and this has been shown to reduce
ulcer recurrence; however, no effect on ulcer healing has been demonstrated. Surgery also has low patient
acceptance, but novel, minimally invasive, endovenous methods have increased in popularity in recent
years. Cohort studies have suggested that early endovenous ablation of superficial venous reflux can
reduce time to healing, yet no robust evidence currently exists to demonstrate the clinical effectiveness or
cost-effectiveness of this approach.
Objectives
The primary objective was to determine the clinical effectiveness and cost-effectiveness of compression
therapy with early endovenous ablation of superficial venous reflux compared with compression therapy
with deferred endovenous ablation in patients with venous ulceration. The secondary objectives were to
investigate the ulcer-free time to 1 year, assess patient quality of life and evaluate the technical success of
the endovenous ablation in the group that received early ablation.
Methods
Design
This was a pragmatic, two-arm, multicentre, parallel, open randomised controlled trial with a health economic
evaluation.
Setting
The setting was 20 secondary care vascular centres across England with ability to provide early endovenous
ablation and established referral pathways for patients who have venous ulceration.
Participants
Written informed consent was obtained from all participants, who then underwent clinical assessment and
duplex Doppler ultrasound examination to assess eligibility for entry to the trial. For patients with bilateral
venous ulcers, the worse leg according to the patient was included and designated the ‘reference leg’.
Inclusion criteria
l Active leg ulceration of duration > 6 weeks but < 6 months.
l Able to give informed consent to participate in the trial after reading the patient information
documentation.
l Aged ≥ 18 years.
l Ankle–brachial pressure index of ≥ 0.8.
l Primary or recurrent superficial venous reflux on colour duplex Doppler ultrasonography assessment
(defined as retrograde flow of > 0.5 seconds in superficial veins and > 1 second in deep veins) deemed
to warrant endovenous ablation by the treating clinician.
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Exclusion criteria
l Patients who are unable to tolerate compression therapy.
l Inability of the patient to receive early endovenous ablation by recruiting centre.
l Pregnancy (female participants of reproductive age were eligible for inclusion in the trial, subject to a
negative pregnancy test prior to randomisation).
l Leg ulcer of non-venous aetiology (as assessed by the responsible clinician).
l Ulcer deemed to require skin grafting (as assessed by the responsible clinician).
Randomisation
Randomisation lists were created using randomly permuted blocks and stored in a secure online location.
Eligible patients were automatically assigned the next available entry in the appropriate list. Participants
were randomised 1 : 1 to either early or deferred endovenous ablation.
Interventions
Participants in the early-ablation group received compression therapy and endovenous ablation of superficial
venous reflux within 2 weeks of randomisation. For participants randomised to deferred ablation, treatment
consisted of compression therapy followed by endovenous ablation once the ulcer had healed. Multilayer
elastic compression (two, three or four layer), short-stretch compression and compression hosiery were all
permitted. Ablation was allowed in the deferred ablation group if the ulcer had not healed within 6 months
of randomisation. Endovenous laser ablation or radiofrequency laser ablation, ultrasonography-guided
foam sclerotherapy, cyanoacrylate glue and mechanochemical endovenous ablation were all permitted; the
individual ablation modality was decided by each clinician on a case-by-case basis. However, the endovenous
ablation had to include ablation of truncal venous reflux (to the lowest point of incompetence) and ablation
of any significant reflux identified on a further duplex Doppler ultrasonography scan performed 6 weeks
after randomisation. Once the ulcer had healed, participants were provided with and advised to wear elastic
stockings as per local guidelines.
Follow-up
Participants in the early-ablation group underwent duplex Doppler ultrasonography at 6 weeks post
randomisation to assess the technical success of the ablation procedure. Participants were contacted on a
monthly basis to determine ulcer healing dates with disease-specific [Aberdeen Varicose Vein Questionnaire
(AVVQ)] and generic [EuroQol-5 Dimensions, five-level version (EQ-5D-5L) and Short Form questionnaire-36
items (SF-36)] quality of life questionnaires at baseline, 6 weeks and 6 and 12 months.
Main outcome measures
The primary outcome measure was time to ulcer healing from randomisation, confirmed by blinded core
laboratory assessment. Secondary outcomes included 24-week ulcer healing rates, ulcer-free time, Venous
Clinical Severity Score (VCSS), technical success, costs and quality of life. Ulcer healing was defined as
complete re-epithelialisation in the absence of a scab, with no dressing required. If the participant or clinical
care teams suspected that the ulcer was healed, a series of digital photographs (once per week for up to
4 weeks) were taken and assessed by blinded clinical experts.
A within-trial cost-effectiveness analysis was undertaken at 1 year. In the base-case analysis, only complete
cases were included. The price year was 2015–16 and the perspective was the UK NHS and Personal Social
Services. No discounting was applied in the 1-year analysis. Only resource items related to the venous leg ulcer
or treatments were included in the total mean cost. Quality-adjusted life-years (QALYs) were estimated from
EQ-5D-5L using the crosswalk tariff recommended by the National Institute for Health and Care Excellence
in August 2017 [EuroQol.org. NICE position statement on the EQ-5D-5L. 2017. URL: https://euroqol.org/
nice-position-statement-on-the-eq-5d-5l/ (accessed 15 May 2019)]. Uncertainty was estimated using bootstrap
methods. Sensitivity analyses were carried out using multiple imputation of missing data, using an alternative
tariff for the EQ-5D-5L instrument and assuming a bivariate normal distribution for costs and QALYs. All analyses
were performed on an intention-to-treat basis using Stata® v14.2 (StataCorp LP, College Station, TX, USA), with
statistical significance set at the two-sided 5% level.
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Results
In total, 450 participants were randomised into the trial (224 into the early-ablation group and 226 into
the deferred-ablation group). An unadjusted Cox regression model, with recruitment centre as a random
effect, demonstrated that ulcer healing was quicker in the early-ablation group than in the deferred-
ablation group [hazard ratio (HR) 1.38, 95% confidence interval (CI) 1.13 to 1.68; p = 0.001], with median
time to ulcer healing being 56 (95% CI 49 to 66) days in the early-ablation group, compared with 82
(95% CI 69 to 92) days in deferred-ablation group. Adjusting for participant age, ulcer duration and size
gave similar results (HR 1.42, 95% CI 1.16 to 1.73; p = 0.001).
Kaplan–Meier estimates of 24-week ulcer healing rates, which are unadjusted, were higher in the
early-ablation group than in the deferred-ablation group (85.6%, 95% CI 80.6% to 89.8% vs. 76.3%,
95% CI 70.5% to 81.7%, respectively). Similarly, a post hoc analysis showed a 12-week healing rate of
63.5% (95% CI 57.2% to 69.8%) in the early-ablation group, compared with 51.6% (95% CI 45.2% to
58.3%) in the deferred-ablation group. At 1 year, ulcer healing had occurred in 89.8% of randomised
participants overall (n/N = 404/450): 93.8% (n/N = 210/224) in the early-ablation group and 85.8%
(n/N = 194/226) in the deferred-ablation group. There was a 7.9% (95% CI 2.3% to 13.5%) absolute
difference in healing rates between the groups.
Recurrence rates at 1 year were calculated as a proportion of the participants in whom the ulcer had healed.
By 1 year post randomisation, 24 of 210 (11.4%) participants in the early-ablation group and 32 of 194
(16.5%) participants in the deferred-ablation group had experienced ulcer recurrence.
Ulcer-free time was determined only in participants who completed 1 year of follow-up and the difference
between the early-ablation and deferred-ablation groups was assessed using the Mann–Whitney U-test.
Median ulcer-free time over 1 year was 306 [interquartile range (IQR) 240–328] days (n = 204) in the early-
ablation group, compared with 278 (IQR 175–324) days (n = 203) in the deferred-ablation group (p = 0.002).
The results were not affected when adjustments were made for participant age, ulcer size, ulcer duration
and recruitment centre. Participants in the early-ablation group were more likely to have a longer ulcer-free
time of being in a higher quartile of ulcer-free time (odds ratio 1.54, 95% CI 1.07 to 2.21; p = 0.02).
Mean VCSS was similar in the two trial groups at baseline {15.8 [standard deviation (SD) 3.3] in the
early-ablation group and 15.7 [SD 3.1] in the deferred-ablation group}. At 6 weeks, mean VCSS was 10.5
(SD 4.7) in early-ablation group and 12.6 (SD 4.4) in the deferred-ablation group.
At baseline, AVVQ, EQ-5D-5L and SF-36 scores were similar in the early- and deferred-ablation groups.
When compared over the whole follow-up period, there were significant differences in repeated measures
of AVVQ score between the two groups (p < 0.001), with lower scores (indicating better disease-specific
quality of life) seen in the early-ablation group. Significant differences over time were also observed
between the groups in EuroQol-5 Dimensions index value (p = 0.03) and SF-36 body pain (p = 0.05),
again with more favourable scores in those randomised to early ablation; however, differences between
the groups for the other generic quality-of-life measures were not significant. The most common
complications of endovenous ablation were pain and asymptomatic deep-vein thrombosis.
The base-case economic analysis (complete cases only) included 173 participants in the early-ablation
group and 171 in the deferred-ablation group. This analysis showed insignificant differences in total mean
cost per patient over 1 year between early and deferred ablation {mean difference £163 [standard error
(SE) £318]; p = 0.607}. The greater initial mean cost of the early-ablation strategy was partly offset by the
reduced cost of treating unhealed leg ulcers in this group. There was, however, a substantial and statistically
significant gain in QALY over 1 year, with the mean difference being 0.041 (SE 0.017; p = 0.017). The
incremental cost-effectiveness ratio of early ablation at 1 year was, therefore, £3976 per QALY, compared
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with deferred ablation, with a high probability (89%) of early ablation being more cost-effective at
conventional UK decision-making thresholds (currently £20,000 per QALY). Sensitivity analyses using
alternative tariffs for EQ-5D-5L, a bivariate normal distribution for costs and QALYs, and multiple
imputation of missing data found similar results.
Conclusions
Early endovenous ablation of superficial venous reflux in addition to compression therapy reduces the time
to healing of venous leg ulcers, increases ulcer-free time and is highly likely to be cost-effective.
Implications for health care
Findings from this trial suggest that early diagnosis and endovenous ablation of superficial venous
reflux in addition to compression therapy can accelerate healing of venous leg ulcers and produce health
economic benefits. Implementation of early diagnosis and endovenous ablation of superficial venous reflux
will require further development of care pathways between primary and secondary care.
Recommendations for research (numbered in order of priority)
1. Carry out a longer-term follow-up to determine if early endovenous ablation influences ulcer recurrence
rates in the medium and long term.
2. Evaluate the benefit of early ablation for superficial venous reflux in patients with venous leg ulceration
of > 6 months duration.
3. Determine the implications of deep-venous incompetence and occlusive disease and the potential role
of deep-venous stenting to improve venous outflow of the limb.
4. Evaluate the optimal technique and the extent of eradication of superficial venous incompetence in
patients with venous ulceration.
Trial registration
This trial is registered as ISRCTN02335796.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Background of venous leg ulcers
Leg ulcers are open ‘sores’ on the lower limbs situated between the ankles and knees, and were defined in
this trial as those that fail to heal within 6 weeks. These ulcers represent a source of great discomfort and
social isolation to patients, who often complain of associated pain, odour and wound discharge. Ulcers
often take many months to heal, meaning that the condition is also frustrating for health-care professionals
involved in their management in hospital and community settings. In 70% of cases, the underlying cause of
leg ulceration is lower limb venous disease, sometimes evident as varicose veins but often undetectable by
visual examination alone.1 The prevalence of venous leg ulcers in the adult population overall has been
estimated at 0.03–1%, rising dramatically in those aged > 80 years.2–4 As patients with venous ulceration
often suffer episodes of recurrence, the number of patients at high risk of ulceration may actually be four-
to fivefold higher.5 It should also be noted that, with an ageing and increasingly obese population,6 the
incidence and prevalence of venous ulceration are both likely to increase. Treatment of the condition in the
UK incurs a substantial cost burden, estimated at £400M–600M per annum,7 although the figure could be
higher.8
Venous ulcers are characterised by protracted healing times. Despite recent advances in the management of
patients with venous ulcers, 24-week healing rates in published randomised trials are around 60–65%,9,10
and the true population healing rates are likely to be significantly lower. Some ulcers may never heal, and
patients whose ulcers do heal are at high risk of recurrent ulceration. These poor outcomes are likely to be a
reflection of the severe underlying venous disease (reflux and, less commonly, obstruction) in this patient
group, although inadequate assessment and suboptimal treatment of the venous disease are also likely to
be important contributing factors.
Pathophysiology of venous leg ulcers
The venous circulation of the lower limb has two components: the deep and superficial systems. Blood
normally flows from the superficial to the deep veins, stimulated by calf and foot muscle contractions.
Blood is prevented from flowing back down the leg under the influence of gravity by ‘one-way’ bicuspid
valves along the deep and superficial veins.
When these valves are damaged, they become incompetent, resulting in venous flow away from the
heart. This results in the superficial veins usually becoming dilated and tortuous (varicose), and the
resulting sustained high venous and capillary pressures lead to skin inflammation and breakdown of
the skin, visible as ulceration.11 The deep veins also have valves, which may also become incompetent
and cause high venous pressure, but are not visible on the skin.
Duplex Doppler ultrasonography studies12–14 of patients attending leg ulcer clinics suggest that around 50%
of patients with venous leg ulcers have disease only of the superficial veins, with a further 30–40% having
a mixture of superficial and deep-venous disease. Surgical treatment of the superficial venous reflux can
benefit both of these groups of patients, in terms of reducing ulcer recurrence.15 Approximately 5–10%
of patients with venous ulcers have diseased deep-venous systems only and are not amenable to surgical
correction with current technology. These patients are usually treated with compression therapy alone.
DOI: 10.3310/hta23240 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 24
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Gohel et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
1
Conservative management
Ulcer healing strategies are based on efforts to reduce the reflux of blood back down the leg and into the
skin, as this is considered the most significant cause of high venous pressure and ulceration in most patients.
Longstanding venous hypertension has been shown to cause a number of changes to the microcirculation
in the lower leg, which can contribute to the chronic skin changes or eventual ulceration associated with
chronic venous disease.16
The mainstay of therapy for venous ulceration is compression therapy, which was first described around
2000 years ago. Compression bandaging is used to heal venous ulceration by counteracting the gravitational
force on the blood, in effect temporarily replacing the incompetent valves.17 Bandages are usually reapplied
once to four times per week.
A Cochrane review18 of the effectiveness of compression reviewed 48 randomised controlled trials (RCTs)
and found that the use of compression improved healing rates compared with no compression use and that
multicomponent bandages are more effective than single-component systems, with two-component systems’
healing rates being equivalent to four-layer bandaging. An individual patient data meta-analysis18 found faster
healing with four-layer bandaging use than with short-stretch bandaging use, and improved healing rates
at 2–4 months using high-compression stockings compared with short-stretch bandaging. In addition, the
meta-analysis showed the four-layer bandaging to be more cost-effective than short-stretch bandaging.18
The haemodynamic benefit of compression is lost almost immediately after removal of compression, and
so compression offers a treatment benefit only while in situ.19 There are also side effects associated with
compression, such as pressure damage, which can lead to reduced concordance rates, as highlighted by a
recent Cochrane review.20
Treatment options for superficial venous reflux
The treatment of superficial venous reflux offers a logical strategy for reducing chronic venous hypertension
and so improving the healing of venous leg ulcers. Diseased superficial veins can be surgically removed
(or ‘stripped’) by open varicose vein surgery or ablated using endovenous interventions without harming the
overall venous function of the leg, theoretically removing a causative factor for recurrence of the ulcer after
the compression bandaging has ceased.
Open surgery
For over a century, the treatment of superficial venous reflux has involved operative ligation and stripping
of the vein and avulsion of bulging varicose veins.21 Until recent years, open surgery has been considered
the definitive treatment option for superficial venous reflux. However, the operation usually requires
general anaesthesia, and patients often suffer discomfort, bruising and significant time off work in the
postoperative period. Long-term studies have also identified significant complications of open surgery,
including nerve damage and recurrence of varicose veins, seen in > 60% of patients at 11 years in one
randomised study.22
Endovenous interventions
In response to this high complication rate and a growing patient desire for less invasive treatments, a range
of novel, minimally invasive, endovenous treatment options have been developed and have gained in
popularity over the last 10–15 years. Interventions such as ultrasonography-guided foam sclerotherapy
(UGFS),23 endovenous laser ablation (EVLA)24 or radiofrequency laser ablation (RFA)25 can be performed
using local anaesthesia in an outpatient setting. Newer endovenous interventions include mechanochemical
endovenous ablation (MOCA) and cyanoacrylate glue closure. These treatments involve cannulation of
the vein to be treated, usually under ultrasonography guidance, obliteration and closure of the refluxing
superficial veins by either chemical (e.g. foam sclerosant, glue) or thermal ablation (e.g. RFA, EVLA, steam).
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Numerous randomised studies have demonstrated that endovenous modalities result in comparable vein
closure rates to open surgery, but are clearly superior in terms of complications and recovery.26–28
Each of the different endovenous modalities has potential advantages and potential disadvantages, although
all are less invasive than traditional open surgery. This is of particular relevance to patients with venous ulcers,
who are often elderly and may have several comorbidities and for whom surgical procedures involving general
anaesthesia may be inappropriate. Endovenous techniques can also be performed without discontinuing
anticoagulation therapy, which is increasingly prescribed in this patient population.
Existing research
The ESCHAR randomised controlled trial
Aims and results
The most significant trial of superficial venous intervention in patients with venous ulceration is the Effect
of Surgery and Compression on Healing And Recurrence (ESCHAR) trial (ISRCTN07549334).9,15 The trial
aimed to evaluate the role of traditional superficial venous surgery in reducing ulcer recurrence in patients
with open or recently healed venous ulcers. Following prospective observational studies to inform power
calculations, a total of 500 participants were randomised to compression therapy alone or to compression
with open surgery for superficial venous reflux. The group randomised to surgical treatment had
significantly lower venous ulcer recurrence rates at 4 years (Figure 1).
Analysis stratified by pattern of venous reflux demonstrated that this clinical benefit was present for
patients with isolated superficial venous reflux and patients with superficial and segmental deep reflux.
This clearly indicated that the majority of patients with venous ulceration could benefit from superficial
venous intervention.
The ESCHAR trial was unable to detect an effect of surgery on ulcer healing (Figure 2). This finding has led
many to conclude that treatment of venous reflux does not have a role in patients with open ulcers.
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FIGURE 1 The ESCHAR trial: ulcer recurrence. Reproduced from Long term results of compression therapy alone
versus compression plus surgery in chronic venous ulceration (ESCHAR): randomised controlled trial, Gohel MS,
Barwell JR, Taylor M, Chant T, Foy C, Earnshaw JJ, et al.,15 vol. 335, p. 83, 2018, with permission from BMJ
Publishing Group Ltd.
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Weaknesses
There were, however, several limitations to the evidence from the ESCHAR trial. The trial was not powered
to assess ulcer healing, as both patients with open ulcers and those with healed ulcers were included.
The statistical power was further weakened by a high crossover rate, as around one-fifth of participants
randomised to surgery later decided that they did not want to have the operation. Moreover, participants
who consented to surgery waited a median of 7 weeks for intervention and so did not receive an
immediate benefit. Consequently, some smaller ulcers might have already healed with compression
bandaging. Finally, some of the surgical procedures used were suboptimal when judged by current
standards and the use of local anaesthetic may have meant that some legs were left with residual venous
incompetence. Thus, it is likely that the benefits of treating superficial venous reflux were underestimated
in this trial, particularly for the assessment of ulcer healing. The poor patient acceptance of surgery
emphasises the need for a minimally invasive superficial venous treatment modality in this patient group.
Other relevant research
In a smaller Dutch randomised trial, 170 patients (200 legs) were randomised to compression alone or
compression with surgical treatment of superficial reflux (including subfascial endoscopic perforator surgery).10
Although there was no statistically significant difference between healing rates with compression and surgery,
the trial was underpowered and the results were compatible with improved ulcer healing rates and greater
ulcer-free time in the group randomised to surgery.
The Ulcer Surgery as Adjuvant to compression Bandaging for Leg UlcErs (USABLE) trial29 randomised
76 patients with venous ulceration to four-layer compression bandaging or compression plus superficial
venous surgery. Time to ulcer healing was similar between the groups.29
Despite the widespread acceptance of endovenous modalities, few published prospective studies have
reported outcomes in patients with leg ulcers. The Cochrane systematic review did not identify any eligible
RCTs;30 another systematic review31 identified one RCT32 and, although this trial did not meet the quality
criteria for inclusion in the Cochrane review, it found that endovenous thermal ablation significantly
increased the probability of ulcer healing compared with compression alone [risk ratio 3.40, 95%
confidence interval (CI) 1.65 to 6.98].
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FIGURE 2 The ESCHAR trial: ulcer healing. Reproduced from Long term results of compression therapy alone versus
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One retrospective cohort study of 170 patients with active or healed leg ulceration (195 legs) treated with
EVLA achieved excellent healing rates and low recurrence rates of 16%, as did another study of 173 legs,
which noted that ulcer healing and recurrence rates were similar to those seen with surgical stripping.33,34
In a prospective study of 186 patients with leg ulceration treated with UGFS, the ulcer healing rate was
> 70% and the patient acceptability of treatment was excellent.35 In a further study of foam sclerotherapy
in 130 patients, a healing rate of 82% was achieved.36
Unsurprisingly, endovenous interventions are very acceptable to patients, and reported complication rates
are low.37 A recent meta-analysis demonstrated that clinical outcomes following endovenous interventions
outcomes are comparable with those achieved with open surgery, but with lower complication rates of
pain, infection and bruising, and faster/earlier return to work.38
Although these studies lend support to the hypothesis that early endovenous ablation to correct superficial
venous reflux may accelerate venous ulcer healing, a large randomised trial is required to provide reliable
evidence and guide modern practice.
Current UK national guidelines
Scottish Intercollegiate Guidelines Network: 2010
The most current ulcer-specific guidance, issued by the Scottish Intercollegiate Guidelines Network in
2010,39 concluded that the optimal management of patients with venous ulceration includes the treatment
of refluxing superficial veins to reduce the risk of ulcer recurrence based on the results of the ESCHAR trial.
National Institute for Health and Care Excellence guidelines: 2013
The National Institute for Health and Care Excellence (NICE) published guidance on the diagnosis and
management of varicose veins in July 2013;40 it recommends the referral of patients with symptomatic
varicose veins (including current or healed ulceration) to a vascular service within 2 weeks. Vascular service
has been defined by NICE as:
. . . a team of healthcare professionals who have the skills to undertake a full clinical and duplex
ultrasound assessment and provide a full range of treatment.
© NICE 2013 Varicose veins: diagnosis and management.40 Available from www.nice.org.uk/guidance/
cg168/chapter/key-priorities-for-implementation. All rights reserved. Subject to Notice of rights
<https://www.nice.org.uk/terms-and-conditions#notice-of-rights>. NICE guidance is prepared for the
National Health Service in England. All NICE guidance is subject to regular review and may be updated
or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication
Despite a study noting an increase in referrals to secondary care in the period after implementation, results
were unable to demonstrate an impact on early referral.40,41 The NICE guidance also recommends the use
of venous duplex ultrasonography to confirm the presence of venous insufficiency and endovenous
intervention as first-line treatment.42
National Institute for Health and Care Excellence quality standard: 2014
The NICE quality standard on the diagnosis and management of varicose veins of the legs43 was published
in August 2014 and provides specific, concise and measurable statements to improve the process and care
of patients with varicose veins. This quality standard echoed the 2013 NICE guidance in terms of referral,
diagnosis and treatment choice.
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Rationale for the Early Venous Reflux Ablation trial
Despite the evidence that the treatment of superficial venous reflux reduces ulcer recurrence in patients
with venous leg ulcers, there is currently no level 1 evidence demonstrating reductions in time to healing.21
With this void in evidence, superficial venous reflux is often treated after ulcers have healed following
conservative treatment involving compression bandaging. The danger of taking this approach is that, once
the ulcer is healed and the symptoms have resolved, patients may not be referred. The resulting untreated
superficial venous reflux contributes to an increased risk of ulcer recurrence, which is both costly for the
health service and distressing for the patient. The previous RCT literature may have underestimated the
clinical benefit of intervention, with recent prospective cohort studies of endovenous intervention in
active leg ulceration clearly suggesting an adjuvant benefit compared with compression alone in terms of
healing rates. Time to healing has been highlighted as the end point that is most important to patients,
as demonstrated in the patient and public involvement (PPI) work (see Appendix 1) of this trial and even a
modest improvement in ulcer healing would significantly reduce the health-service costs associated with
the condition.
As the incidence and prevalence of venous ulcers are likely to increase as a result of the ageing population,
it is important to clarify the role and timing of superficial endovenous ablation in venous ulceration to
guide treatment recommendations and referral pathways.44,45
Summary of main points
Venous leg ulcers are open wounds that have a detrimental effect on the quality of life of patients.
Treatment of the condition in the UK represents a substantial economic burden to the NHS and Personal
Social Services, amounting to many hundreds of millions of pounds per year.
Until recently, superficial venous reflux could be treated only by open surgery. Newer, endovenous techniques
have been shown to be just as effective as open surgery in terms of clinical improvement, but with reduced
complications and pain. These techniques do not need to be performed under general anaesthetic and
therefore may be more suitable for elderly patients with significant comorbidities. The most recent UK
guidelines for varicose veins43 recommend early referral to a vascular service for diagnosis and first-line
treatment by means of endovenous interventions.
The ESCHAR trial9,15 indicated that the majority of patients with venous ulceration could benefit from
superficial venous intervention with respect to ulcer recurrence; however, the study was not powered to
detect an effect on ulcer healing and therefore further research into ulcer healing was required.
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Chapter 2 Methods
Research objectives
Primary objective
The primary objective was to determine the clinical effectiveness and cost-effectiveness of compression
therapy with early endovenous ablation of superficial venous reflux compared with compression therapy
with deferred endovenous ablation in patients with venous ulceration.
Secondary objective
The secondary objective was to investigate ulcer-free time, quality of life, and the clinical and technical
success of endovenous ablation to 1 year.
Trial design
We conducted a pragmatic, multicentre, open RCT with participants randomised 1 : 1 to either (1) deferred
(standard) therapy, consisting of multilayer elastic compression therapy, with deferred endovenous ablation
of superficial reflux once the ulcer has healed, or (2) early endovenous ablation of superficial venous reflux
(within 2 weeks) in addition to standard compression therapy.
Amendments to the protocol
Substantial amendments to the trial protocol were submitted after the initial approval, in order to increase
recruitment and retention, correct the sample size calculation and clarify the health economic evaluation:
l Version 2.0, dated 6 January 2014: amended to provide a clearer definition of ulcer healing, clarify the
per-protocol analyses and safety sections, and to clarify that participants could be offered endovenous
ablation of superficial venous reflux in the deferred group if their ulcer had not healed at 6 months.
l Version 3.0, dated 10 March 2014: amended in order to allow the display of posters and dissemination
of leaflets and participant information sheets in primary care sites.
l Version 4.0, dated 16 March 2016: amended to correct the sample size from 500 participants to
450 participants (which was originally calculated erroneously), and to allow for a reduction in the
number of photograph verification visits performed if the core laboratory confirms that the ulcer is
healed in order to prevent unnecessary visits and enhance participant retention.
l Version 5.0, dated 6 April 2017 [see the project web page: www.journalslibrary.nihr.ac.uk/programmes/
hta/11129197/#/ (accessed 23 April 2019)]: amended to (1) incorporate a Health Technology Assessment
(HTA) funding extension to allow for the collection of longer-term follow-up during October 2018 and
March 2019 and (2) make revisions to the health economics section to clarify and update the protocol
to reflect new National Institute for Health Research (NIHR) guidelines. The follow-up period is now
complete (31 March 2019) and, at the time of publication, we are cleaning and locking the database
prior to data analysis.
Ethics and research and development approvals
A favourable ethics opinion was given by the National Research Ethics Service Committee South West –
Central Bristol on 15 August 2013 (reference number 13/SW/0199). For a copy of the original approval
see Report Supplementary Material 1. Annual reports were submitted to this committee, which confirmed
that the ethics approval continued to apply.
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The study-wide governance review was undertaken by the Clinical Research Network North West London in
August 2013. Research and development NHS approvals were granted at participating sites between October
2013 and March 2015. The trial was granted the new Health Research Authority approval on 30 June 2016.
Sponsorship
The trial was sponsored by Imperial College London.
Trial management
The trial was supported by the Imperial Clinical Trials Unit (ICTU) and the day-to-day trial management
was performed by the trial manager based in the academic vascular department of Charing Cross Hospital,
London. The trial manager was responsible for co-ordinating the data collection; follow-up; data cleaning;
monitoring visits; communication with the sites, participants and collaborators; and answering trial-specific
queries. The trial manager and chief investigator met at least monthly during the course of the trial.
Trial Management Group
The trial was supervised by the Trial Management Group, which comprises the chief investigator, lead
statistician, trial statistician, health economist and trial manager. The Trial Management Group met in
person or by teleconference on a regular basis.
Trial Steering Committee
An independent Trial Steering Committee (TSC) was established as per the HTA TSC terms of reference to
oversee trial conduct. The membership comprises five independent members (see Acknowledgements), the
chief investigator, trial manager and lead statistician. The TSC met at least annually or more regularly if
required, as decided by the committee. For the meeting dates see Appendix 2.
Data Monitoring Committee
An independent Data Monitoring Committee (DMC) was established as per the HTA DMC terms of
reference, to monitor trial data and safety. The membership comprised four independent members
(see Acknowledgements). The members met once prior to the start of the trial to agree the DMC charter
and then on an annual basis to review recruitment, fidelity, retention and unblinded comparative data
(for both safety and efficacy). No interim analyses were planned and the trial statistician was the only
member of the trial team to have access to the unblinded data. Following each meeting, the DMC
recommended continuation of the trial to the TSC. For the meeting dates see Appendix 2.
Participants
All patients aged ≥ 18 years presenting with a leg ulcer of venous origin who were able to tolerate compression
therapy and were suitable for endovenous ablation of superficial venous reflux could be included.
Inclusion criteria
Patients with all of the criteria listed below were deemed eligible:
l current leg ulceration duration of > 6 weeks’ but < 6 months
l able to give informed consent to participate in the trial after reading the patient information documentation
l patient aged ≥ 18 years
l ankle–brachial pressure index (ABPI) of ≥ 0.8
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
8
l primary or recurrent superficial truncal venous reflux on colour duplex assessment deemed by the
treating clinician to be significant enough to warrant endovenous ablation.
Patients who could not speak/understand English were eligible for inclusion. Informed consent was obtained
with assistance from translation services as per standard clinical practice; however, in view of the lack of
cross-cultural validation for quality-of-life tools, only healing outcome data were collected.
Exclusion criteria
Patients meeting any of the criteria listed below were ineligible:
l presence of deep-venous occlusive disease or other conditions precluding endovenous superficial
venous ablation (at the discretion of the treating clinician)
l patients unable to tolerate multilayer compression therapy (as concordance with compression therapy
can be variable for patients at different times, patients who were generally concordant with
compression, but unable to tolerate short periods, were still deemed eligible)
l inability of the patient to receive prompt endovenous ablation by recruiting centre
l pregnancy
l leg ulcer of non-venous aetiology as assessed by the treating clinician
l patients deemed to require skin grafting as assessed by the treating clinician.
Sample size
The sample size calculation for this trial was based on the primary outcome of time to ulcer healing.
In the ESCHAR trial, the 24-week healing rate in participants randomised to compression alone was
approximately 60%.46 Two prospective studies evaluating the early endovenous ablation of superficial
venous reflux suggested that the 24-week healing rate may be as high as 82%.35,36
In order to calculate a sample size for this trial, the desirable absolute benefit associated with early
endovenous ablation of superficial truncal reflux was estimated to be 15%. Assuming that the 24-week
healing rate in the deferred (standard) group is 60%, to identify an absolute difference in 24-week healing
rates between the two groups of 15% (60% vs. 75%), with 90% power and allowing for 10% dropout,
the trial required 416 subjects (208 in each group, 254 healed leg ulcers in total).47 To incorporate further
allowances for protocol violations and unexpected dropouts, the target sample size was set at
450 participants.
Settings and locations
Participants were recruited from the vascular departments of 20 secondary care NHS trusts throughout
England: Bradford Teaching Hospitals NHS Foundation Trust, Cambridge University Hospitals NHS
Foundation Trust, Frimley Health NHS Foundation Trust, Gloucestershire Hospitals NHS Foundation Trust,
Heart of England NHS Trust (now University Hospitals Birmingham NHS Foundation Trust), Hull and East
Yorkshire Hospitals NHS Trust, Imperial College Healthcare NHS Trust, Leeds Teaching Hospitals NHS
Trust, North Cumbria University Hospitals NHS Trust, North West London Hospitals NHS Trust, University
Hospitals Plymouth NHS Trust, Salisbury NHS Foundation Trust, Sheffield Teaching Hospitals NHS
Foundation Trust, Taunton & Somerset NHS Foundation Trust, The Dudley Group NHS Foundation Trust,
the Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Royal Wolverhampton NHS
Trust, University Hospital Birmingham NHS Trust, Worcestershire Acute Hospitals NHS Trust, and York
Teaching Hospital NHS Foundation Trust. For a list of participating hospitals see Acknowledgements,
Local vascular research teams.
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Recruitment procedure
Prior to commencing the trial, information was disseminated to general practices in each recruiting region.
In addition, selected primary care trusts (PCTs) not currently involved in the trial were set up as patient
identification centre sites displaying posters and leaflets and disseminating patient information sheets to
patients once the protocol amendment had been approved. As per the July 2013 NICE guidelines on
varicose veins,40 patients with venous ulcers were required to be referred from primary to secondary care
as part of the standard care pathway.
Patients were screened from secondary care vascular, ulcer and tissue viability clinics. As part of standard
care, patients are evaluated by clinical assessment and colour duplex examination. Depending on the
results of these tests, the patients were given a short leaflet containing a summary of the trial and,
if interested, then given the more detailed patient information sheet to read.
The details of patients who were eligible for the trial but did not agree to participate, and patients with
ulcers who were not eligible for the trial, were recorded anonymously on screening logs along with a
minimal data set (including age, ulcer duration and venous duplex/ABPI findings, if known, and reason
for non-inclusion).
Informed consent
Patients were given a minimum of 24 hours to consider the trial in addition to the opportunity to discuss
all aspects of the trial with their family and/or general practitioner (GP). Patients were then contacted by
telephone by the research nurse so that any further questions could be answered. All willing patients were
booked in to the leg ulcer clinic to undergo a baseline visit.
Written consent was obtained from each participant at the baseline visit. The patient information sheet and
informed consent form (see Report Supplementary Material 2) both refer to the possibility of long-term
follow-up if the trial is extended and seek permission to access to their NHS records for these purposes. With
the participant’s consent, a letter was also sent to the participant’s GP (see Report Supplementary Material 3).
A copy of the patient information sheet and informed consent form was filed in the participant’s hospital
notes and the local research file and a copy was also given to the participant.
All trial documentation contained the contact details of the Early Venous Reflux Ablation (EVRA) trial chief
investigator and trial manager to enable participants to obtain further information from the trial team if
required.
Baseline assessment
Once written consent was given by the participant, eligibility was confirmed and baseline data were
collected by the research nurse using the case report form (CRF) (see Report Supplementary Material 4).
Participant demographic and contact details
Data collected included participant contact details, GP details, age, sex, ethnicity and work status.
Pregnancy tests were taken by women of child-bearing potential. Participants were provided with a
reminder wallet card, which contained the contact details of the local research nurse with a reminder
message to call the nurse when they thought that their ulcer had healed.
General medical and ulcer history
This included body mass index (BMI), ABPI, medical history and current medications. An ulcer history was
taken, including any previous ulcers and interventions.
METHODS
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Current ulcer and venous assessment
Ulcer duration and size
For the leg to be randomised, the duration of the current ulcer (according to the participant and available
medical records) and ulcer size were recorded.
To measure the total ulcer area, tracing grids of 1 cm2 squares were placed over all the ulcers on the
randomised leg and the outside perimeter of the wounds was traced using an indelible pen. The ulcer area
was determined by totalling the number of squares contained within the traced ulcer/s area. Where more
than one ulcer was present, the total area was calculated by combining each individual area.
In addition, photographs of all the ulcers on the randomised leg were taken with a digital camera,
alongside a measuring scale. Sony Cyber-shot DSC-WX60 16.2 Megapixel Digital Cameras (Sony
Electronics Inc., San Diego, CA, USA) were provided to all sites and a simple photography protocol was
detailed in the site handbook. The tracings and photographs were assigned pseudonyms (trial number)
and transferred via a secure server to the trial manager.
The tracing and photograph protocol is detailed in Appendix 3.
Once follow-up was complete, an exact ulcer area was calculated from the wound grid and photograph
by the use of a software program, ImageJ (Wayne Rasband, National Institutes of Health, Bethesda, MD,
USA; open source).48 By reviewing the photographs and tracings in combination, a judgement was made
of the most accurate measurement to be taken as the total ulcer area.
Clinical ulcer assessment
Clinical, aetiological, anatomical and pathophysiological
Clinical, aetiological, anatomical and pathophysiological (CEAP) is a descriptive classification that was
developed in 1994 by an ad hoc committee of the American Venous Forum in order to standardise the
classification of chronic venous disease.49 The classification was updated in 2004 to refine some of the
definitions and introduce the simpler basis CEAP.50 All participants were classified according to the basic
CEAP. An active ulcer is described by C6, and a healed ulcer as C5.
Venous Clinical Severity Score
The Venous Clinical Severity Score (VCSS) is a component of the Venous Severity Scoring System designed
in 2000 by an ad hoc American Venous Forum committee consensus, in order to compliment the CEAP
classification and quantify the severity of disease and subsequent improvement or decline.51 The VCSS
has 10 components (pain, varicose veins, venous oedema, skin pigmentation, inflammation, induration,
compression used and active ulcer, duration, number and size), each with four categories assigned values
of 0–3. The overall scores can range from 0 (lowest severity) to 30 (highest severity). A score was recorded
at baseline for each participant (Tables 1 and 2).
Suitability for intervention
Details of venous disease were also collected, including previous deep-vein thrombosis (DVT) and pattern of
venous reflux identified on the duplex ultrasound, to assess suitability for ablation. Duplex ultrasonography
scanning was performed as per standard care at the randomising site.
Participant-completed questionnaires
To provide a comparator for participant-reported outcomes, enrolled participants completed three health
questionnaires at baseline. The baseline health questionnaires were administered prior to the participants
being told of their treatment allocation (see Report Supplementary Material 4).
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EuroQol-5 Dimensions
The EuroQol-5 Dimensions (EQ-5D) is a widely recognised, generic tool to measure health outcomes and
has been validated in a variety of patient groups, including those with venous leg ulcers.58 The EQ-5D
questionnaire comprises two sections; the first assesses the participant’s mobility, self-care, ability to
perform usual activities, pain/discomfort and anxiety/depression levels, and the second records the
participant’s self-rated health on a vertical score of 0 to 100 (see Table 1).
Short Form questionnaire-36 items
The Short Form questionnaire-36 items (SF-36) is a generic quality-of-life tool used to determine people’s
physical and mental health. It has been validated in many patient groups, including those with varicose
veins.56 The physical domain measures physical functioning, physical role limitations, body pain and general
health, whereas the mental dimension measures vitality, social functioning, mental health role limitations
and general mental health. Two separate scores are produced (separate physical/mental component
summary scores), in addition to the eight separate domain scores. Each score is measured on a scale of 0
to 100 (worst to best). Scores represent the percentage of total possible score achieved (see Table 1).
Aberdeen Varicose Vein Questionnaire
The Aberdeen Varicose Vein Questionnaire (AVVQ) is a validated patient-reported disease-specific health
questionnaire to assess quality of life in patients with varicose veins. The AVVQ comprises a diagram on
which patients draw on their varicose veins and a questionnaire with 12 questions, half of which require a
response for each leg. The scores range from 0 to 100 (no effect to severe effect)53 (see Table 1).
Randomisation and treatment allocation
Separate randomisation lists for each centre were prepared by a statistician prior to recruitment using
randomly permuted blocks in two block sizes (‘ralloc’ command; Stata® v14.2, StataCorp LP, College
Station, TX, USA) and loaded onto the InForm™ version 4.6 (Oracle® Health Sciences, CA, USA) system.
Access to the allocation sequence was strictly restricted to the statistician and appropriate members of the
InForm technical support team to maintain allocation concealment.
Consenting participants were registered on the InForm integrated trial management system, a web-based
data entry system maintained by the ICTU, and their eligibility for the trial verified. Once eligibility was
confirmed, online randomisation was performed remotely by the research nurse.
TABLE 1 Summary of secondary outcome measures and quality-of-life tools used in the EVRA trial
Details of
outcome
measure Type of assessment Range of scores Comments
VCSS52 Physician-assessed clinical
severity evaluation
0–30 Higher scores indicate more severe venous disease
AVVQ53 Patient-reported disease-
specific quality of life
0–100a Higher scores indicate worse health related to
varicose veins
EQ-5D-5L55 Patient-reported generic
quality of life
0–100 (health scale) Consists of a health scale and health index
(with higher scores indicating better health)
SF-3656 Patient-reported generic
quality of life
0–100 (for each domain) Eight scores covering different domains of health,
with higher scores indicating better health
AVVQ, Aberdeen Varicose Vein Questionnaire; EQ-5D-5L, EuroQol-5 Dimensions, five-level version; QoL, quality of life;
SF-36, Short Form questionnaire-36 items.
a Previous studies have used 0.25 standard deviations as a clinically important difference.54
Reproduced from The New England Journal of Medicine, Gohel et al.57 A randomized trial of early endovenous ablation in
venous ulceration, vol. 378, pp. 2105–14. Copyright © 2018 Massachusetts Medical Society. Reprinted with permission.
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TABLE 2 Venous Clinical Severity Score (revised)
Score None (0) Mild (1) Moderate (2) Severe (3)
Pain or other discomfort (i.e. aching,
heaviness, fatigue, soreness, burning).
Presumes venous origin
None Occasional pain or other discomfort
(i.e. not restricting regular daily activity)
Daily pain or other discomfort
(i.e. interfering with but not preventing
regular daily activities)
Daily pain or discomfort (i.e. limits
most regular daily activities)
Varicose veins: ‘varicose’ veins must be
≥ 3 mm in diameter to qualify in the
standing position
None Few: scattered (i.e. isolated branch
varicosities or clusters). Also includes
corona phlebectatica (ankle flare)
Confined to calf or thigh Involves calf and thigh
Venous oedema: presumes venous origin None Limited to foot and ankle area Extends above ankle but below knee Extends to knee and above
Skin pigmentation: presumes venous
origin. Does not include focal
pigmentation over varicose veins or
pigmentation due to other chronic
diseases (i.e. vasculitis purpura)
None or focal Limited to perimalleolar area Diffuse over lower third of calf Wider distribution above lower
third of calf
Inflammation: more than just recent
pigmentation (i.e. erythema, cellulitis,
venous eczema, dermatitis)
None Limited to perimalleolar area Diffuse over lower third of calf Wider distribution above lower
third of calf
Induration: presumes venous origin of
secondary skin and subcutaneous
changes (i.e. chronic oedema with
fibrosis, hypodermitis). Includes white
atrophy and lipodermatosclerosis
None Limited to perimalleolar area Diffuse over lower third of calf Wider distribution above lower
third of calf
Active ulcer number None 1 2 ≥ 3
Active ulcer duration (longest active) N/A < 3 months > 3 months but < 1 year Not healed for > 1 year
Active ulcer size: diameter (largest active) N/A < 2 cm 2–6 cm > 6 cm
Use of compression therapy Not used Intermittent use of stockings Wears stockings most days Full compliance: with stockings
N/A, not applicable.
Reprinted from J Vasc Surg Venous Lymphat Disord, vol. 1, Marston et al.,52 Multicenter assessment of the repeatability and reproducibility of the revised Venous Clinical Severity Score
(rVCSS), pp. 219–24, © 2013 Society for Vascular Surgery, with permission from Elsevier.
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Each participant was automatically assigned the next available treatment allocation in the appropriate
randomisation list and allocated a unique trial number. The randomisation ratio was 1 : 1 with participants
allocated to either:
l early (within 2 weeks) endovenous ablation of superficial venous reflux in addition to compression
therapy or
l deferred (standard) therapy consisting of multilayer elastic compression therapy with deferred
endovenous ablation of superficial reflux once the ulcer healed.
Blinding
It was not possible to blind either the treating team or the participant to the allocated treatment. The
primary outcome, time to ulcer healing, was determined by two expert assessors who were blinded to
participant details, including the treatment group.
Deferred ablation (standard care): control group
Participants in the deferred (standard) care group were randomised to receive multilayer compression
therapy alone with endovenous ablation of superficial reflux once ulcer healing had been confirmed.
Participants whose ulcer had not healed at 6 months post randomisation or who experienced clinical
deterioration in the active leg ulcer during the control treatment, could be offered endovenous interventions
if it was felt that the participant would benefit from expedited endovenous ablation (at the discretion of the
local responsible clinician). The post-ablation duplex ultrasonography strategy for participants in the standard
care group was left to local policy.
Early ablation: interventional group
Participants in the interventional group were randomised to receive endovenous ablation of superficial
truncal reflux within 2 weeks of randomisation in addition to compression therapy. Post-ablation duplex
ultrasonography was performed 6 weeks from randomisation.
Standardisation of compression therapy
As a wide range of compression types are currently used within the NHS, the specific therapy was left
to the discretion of individual centres and primary care professionals. Multilayer elastic (two, three or
four layer), short stretch and hosiery compression were all deemed acceptable for inclusion in the trial.
All participants were advised to use compression hosiery post healing, in line with local policy.
Endovenous interventions
A wide range of endovenous ablation modalities are currently available and in widespread use. The following
interventions were permitted in the trial: EVLA or RFA, UGFS, mechanochemical ablation and cyanoacrylate
glue closure. These interventions could be performed alone or in combination, as directed by clinical need at
the discretion of the responsible vascular specialist.
METHODS
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It was noted that the interventional strategies varied between institutions and between individual clinicians
within the same department. Heterogeneity existed for site of vein cannulation (and, therefore, the length
of vein ablated), the location of intervention (‘office’ or clinic based vs. operating theatre), interventional
strategy for subulcer venous plexus (to ablate or not), the ablation of visible varicose veins (no treatment,
UGFS or surgical avulsion) and the timing of any secondary interventions. As there was neither current
research evidence nor consensus as to a single, optimal endovenous interventional strategy for superficial
reflux in patients with leg ulceration, local and individual variation was allowed, subject to the following
stipulations:
l The endovenous strategy had to include ablation of the main truncal venous reflux.
l Truncal venous reflux had to be treated to the lowest point of incompetence, where possible.
l Significant (as deemed by the treating clinician) residual/recurrent superficial reflux on the 6-week
duplex scan was to be ablated.
l Participants had to continue with multilayer compression/stockings immediately after ablation.
Participant follow-up
All randomised participants were followed up until one of the following:
l 1 year after randomisation
l the participant chose to withdraw from the trial
l death.
The trial design is summarised in Appendix 4.
As per standard care, participants received routine leg ulcer care in the community and/or hospitals in
accordance with local policies.
Monthly telephone calls/follow-up
Participants were followed up on a monthly basis by research nurses at each local site. The aim of the
telephone follow-up was to assess whether or not the reference ulcer had healed (for ulcers that were
unhealed at the last follow-up), and, in the case of ulcers that were known to have healed, to confirm that
the ulcer remained healed. In cases of ulcer recurrence, the telephone follow-up was used to ascertain the
date of recurrence and of subsequent healing. Information on utility and resource use, dressing changes,
adverse events (AEs) and serious adverse events (SAEs) were also collected.
Six-week clinic visit
All participants underwent a clinical assessment of the reference leg at 6 weeks post randomisation to
determine ulcer healing, in addition to VCSS evaluation and documentation of the current ulcer compression
regimen. A wound tracing was drawn and photographs were taken to document the size of any unhealed
ulcers. Disease-specific and generic quality of life were assessed by means of self-completed questionnaires
(AVVQ, EQ-5D and SF-36).
Venous duplex ultrasonography was performed in participants in the early-ablation group to verify if any
residual superficial venous reflux was present and guide whether or not further interventions were
warranted.
Participant withdrawal
Participants could withdraw from the trial at any time without giving a reason; however, efforts were
made to identify the reason for withdrawal whenever possible.
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Participants who expressed a wish to withdraw from the trial visits were asked to confirm if they agreed to
the trial team retaining their existing trial data and accessing trial-related NHS data; this was documented in
the patient notes. If possible, participants were asked for permission to retain primary outcome data.
Participants who declined endovenous ablation remained in the trial for assessment of primary and secondary
outcomes [and analysis on intention to treat (ITT)] unless they specifically withdrew their consent.
Measurement and verification of primary outcome measure
Time to healing of the reference ulcer (blinded)
The primary outcome measure of this trial was time from randomisation to complete healing of ulcers
on the reference leg. Healing was defined in the protocol as complete re-epithelialisation of all ulceration
on the randomised leg in the absence of a scab (as defined in the ESCHAR trial) with no dressing required.
If either the community nurse or the participant believed that ulcer healing had been achieved, they were
asked to contact the local research centre immediately to trigger an urgent verification assessment by the
research nurse within 1 week.
Ulcer healing was verified by clinical assessment and digital photography repeated weekly for 4 weeks,
unless otherwise agreed by the trial manager. Digital photographs were assigned pseudonyms by trial
number only and transferred via a secure server to the ICTU.
All digital images were assessed by two vascular surgeons blinded to treatment allocation. Each independently
assessed the reference ulcer using a predefined set of decision rules based on those utilised in Venous leg
Ulcer Study IV (VenUS IV)59 (see Appendix 5) to allocate each to one of three categories (healed, not healed or
unsure). Disagreements were resolved through discussion with a third blinded expert reviewer.
When a reference ulcer was deemed to have healed, the date of the photograph in which healing was
recorded was taken to be the date of healing. If healing was confirmed at the first verification visit, the
date of healing notification (by participant or community nurse) was taken as the date of ulcer healing.
Measurement and verification of secondary outcome measures
Ulcer healing
The number of ulcers healed at 24 weeks was reported, in addition to time to ulcer healing, to allow
comparison with other published studies.
Ulcer recurrence/ulcer-free time
Participant-reported ulcer recurrence on the reference leg was recorded by the research nurses for up to
12 months from randomisation or until trial exit, by means of monthly telephone calls to the participant.
Recurrence was verified using patient notes from recent clinic visits whenever possible. When there had
been a recurrence of venous leg ulceration on the reference leg, the dates of recurrence and subsequent
healing, if applicable, were recorded and used to determine ulcer-free time.
Health-related quality of life
In addition to the baseline assessment, health-related quality of life (HRQoL) was measured at 6 weeks,
6 months and 12 months using questionnaires either administered in clinic by the research nurse or sent
by mail to the participant along with a pre-addressed and prepaid envelope. Each questionnaire pack was
identical in content to the baseline questionnaire pack containing the EQ-5D, SF-36 and AVVQ. When
necessary, reminder letters were sent by post to participants if the questionnaires had not been returned.
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Utility and resource use
Participant-reported utility and resource use was collected by the research nurses up to 12 months from
randomisation or trial exit via monthly telephone calls to the participant, or at clinic visits if these occurred
as part of clinical care. The participants were provided at baseline with diaries in which any visits to health-
care providers could be recorded. All utility and resource use data were collected, whether or not deemed
to be related to the reference leg.
Markers of clinical success
Venous Clinical Severity Score
In addition to the baseline visit, the VCSS was assessed by the research nurse or treating clinician at the
6-week clinic visit to allow comparison with the baseline score.
Ablation success
Local principal investigators assessed the presence of residual/recurrent truncal superficial venous reflux
in the early-ablation group at 6 weeks by means of a venous duplex. Residual reflux and any recanalised
segments were noted. When the truncal vein was not successfully closed, further endovenous ablation
procedures were organised. For other patterns of residual or recurrent reflux (such as reflux in tributaries or
perforating veins), the decision whether or not to perform additional endovenous interventions was left to
the discretion of the treating clinician.
Safety monitoring of early ablation
Adverse events
The research nurses collected data regarding the occurrence of AEs during the monthly telephone calls
and from clinic or surgery notes, and reported these to the ICTU via the web-based data capture system.
Only AEs deemed by the local principal investigator to be related to the trial intervention or compression
were recorded. The AEs thought to be related to the interventions are summarised in Table 3. AEs were
reviewed and categorised by the trial manager and chief investigator as procedural complications.
Serious adverse events
As per International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals
for Human Use – Good Clinical Practice (ICH–GCP) guidelines, SAEs were defined as those AEs that result in
death; are life-threatening; require inpatient hospitalisation or prolongation of existing hospitalisation; result
in persistent or significant disability or incapacity; result in congenital anomaly or birth defect; are cancer; or
are other important medical events in the opinion of the responsible investigator (i.e. not life-threatening
or resulting in hospitalisation, but may jeopardise the participant or require intervention to prevent one or
more of the outcomes described previously). All SAEs were recorded, whether or not deemed by the local
principal investigator to be related to the trial intervention or compression.
The research nurses collected data regarding the occurrence of all SAEs via the monthly telephone calls,
clinic or surgery notes, and hospital admission records. These were reported to the ICTU via the web-based
data capture system within 24 hours of the nurses becoming aware of the event and reviewed by the chief
investigator.
All SAEs were also reported by the trial manager to the sponsor and chairperson of the DMC. SAEs were
coded using Medical Dictionary for Regulatory Activities (MedDRA®) version 20.0 [URL: www.meddra.org
(accessed 15 May 2019). MedDRA® terminology is the international medical terminology developed under
the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals
for Human Use. MedDRA® trademark is registered by the International Federation of Pharmaceutical
Manufacturers and Associations on behalf of the International Council for Harmonisation of Technical
Requirements for Pharmaceuticals for Human Use].
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Participant communications
Participants were kept updated on trial progress via the trial Facebook (Facebook, Inc., Menlo Park,
CA, USA) and Twitter (Twitter, Inc., San Francisco, CA, USA) accounts. Two participant newsletters were
circulated during the follow-up stage (for participants who had not withdrawn from the trial), to keep
them updated with trial progress. A newsletter summarising the main results from the EVRA trial was also
sent to non-withdrawn participants.
Statistical methods
The trial analysis was carried out on an ITT basis (all participants remained in the group allocated at
randomisation). Histograms and box plots were used to check the distribution and possible outliers for
continuous variables. Mathematical transformations were applied, when appropriate, in order to render
the continuous variables distribution normally distributed. Continuous variables that follow an approximately
normal distribution were summarised using means and standard deviations (SDs). Skewed continuous
variables were summarised using medians and interquartile ranges (IQRs). Categorical variables were
summarised using frequencies and percentages.
All hypothesis testing was planned to be two-tailed with a 5% significance level and no adjustment for
multiple testing. Analyses were performed using Stata v14.2.
As the randomisation was stratified by centre, when possible, analyses are adjusted by trial centre.
Potentially, this is done by including trial centre as either a fixed or a random effect in any regression models.
As the centres that participated in the trial could be viewed as a random sample of all possible trial centres,
random-effects models were preferred. However, in cases where random-effects models could not be fitted
(e.g. owing to lack of convergence), trial centre was included in models as a fixed effect.
Baseline data
Baseline characteristics, including demographics, medical history, ulcer history and details of current
ulcers, were summarised by treatment group using appropriate descriptive methods for all randomised
participants. Ulcer duration was calculated as the difference between the date the current ulcer appeared
TABLE 3 Adverse events expected to be related to the intervention
Systemic Local
Allergic reaction required local/no treatment Bleeding requiring intervention
Migraine Blistering of skin
Visual disturbance Pressure damage
Fainting Nerve damage
Cough/chest tightness DVT
Systemic infection Haematoma
Pulmonary embolism Participant-reported paraesthesia
Transient ischaemic attack Pigmentation of skin
Stroke Superficial thrombophlebitis
New ulcer
Deterioration of ulcer
Wound infection
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(best estimate based on medical records, referral letters and participant recollection) and the date of
randomisation. Deep vein reflux and/or obstruction was defined as iliac, femoral, popliteal or infrapopliteal
deep vein reflux as shown on duplex scan [for details, see the statistical analysis plan on the project web
page: www.journalslibrary.nihr.ac.uk/programmes/hta/11129197/#/ (accessed 18 April 2019)].
Trial completion
Reasons for trial exit were taken from the end-of-trial form and included completed trial (to 12 months),
lost to follow-up, withdrawn and death.
Statistical analysis
Primary end point
The primary outcome was time to complete healing and we tested the hypothesis that there was no
difference in time to ulcer healing between deferred- and early-ablation groups using a Cox proportional
hazards model. As the randomisation was stratified by centre, centre was also included in the model as a
random effect (shared frailty). The proportional hazards assumption was assessed graphically – by plotting
–ln{–ln[Sˆ(t)]} versus ln(t) and checking that the curves for each level of the covariate are parallel – and also
numerically using Grambsch and Therneau tests. Kaplan–Meier (KM) survival curves were also presented
and, as a subsidiary analysis, we investigated the effect of participant age, ulcer size at baseline and
duration of time to complete healing using Cox regression, with centre included in the model as a random
effect to adjust for potential centre effect [for details, see the statistical analysis plan on the project web
page: www.journalslibrary.nihr.ac.uk/programmes/hta/11129197/#/ (accessed 18 April 2019)].
Participants were censored at the time of last follow-up if they had died, withdrawn or were lost to follow-up
before primary ulcer healing. The follow-up time was 1 year after randomisation, and thus observations of
participants with an unhealed primary ulcer at 1 year after randomisation were also censored.
Secondary end points
Recurrence/ulcer-free time to 1 year and 24-week ulcer healing rate
The effect of the trial intervention on ulcer-free time was investigated after adjusting for potential confounders
[for details, see the statistical analysis plan on the project web page: www.journalslibrary.nihr.ac.uk/
programmes/hta/11129197/#/ (accessed 18 April 2019)], using multiple linear regression if the assumption of
normality was met. If the assumption of normality was not met (there is no suitable transformation), ulcer-free
time was categorised and analysed using appropriate regression methods to adjust for potential confounders.
The number of ulcers healed at 24 weeks and associated 95% CIs were obtained from the KM analysis.
One-year ulcer-free time (in days) in those who had completed follow-up to 1 year was calculated as total
follow-up time (i.e. 1 year) minus the total duration of ulcers, including the primary ulcer and any recurrences.
Quality of Life
The AVVQ was scored in accordance with the manual.53
The SF-36 was scored using QualityMetric Health Outcomes™ scoring software 4.0 (QualityMetric, Lincoln,
RI, USA) for the physical health and mental health dimensions and all eight scales: physical functioning,
role limitations due to physical health, role limitations due to emotional problems, energy/fatigue,
emotional well-being, social functioning, pain and general health.
The index-based values (‘utilities’) were calculated by the EuroQol-5 Dimensions, five-level version (EQ-5D-5L),
crosswalk index value calculator downloaded from the EQ-5D official website.
The HRQoL scores were presented using line plots for each trial group to illustrate trends in AVVQ score,
SF-36 and EQ-5D-5L over time. We planned to report the means and 95% CI of means, or medians and
interquartiles, at each time point (including baseline and 6 weeks and 6 and 12 months after randomisation),
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depending on the distribution of the data. Mixed models with time, age, ulcer size and duration as fixed
effects, and trial centre and patient as nested random effects, were used to estimate differences in HRQoL
scores between the trial groups at each time point and to calculate an overall p-value for the difference in
HRQoL scores between the trial groups.
Markers for clinical success: Venous Clinical Severity Score
Clinical success was assessed using the VCSS, which was measured at baseline and 6 weeks post
randomisation. Any change in VCSS was compared between the two groups using the t-test (assuming
that change in VCSS is normally distributed) or appropriate non-parametric test (if change in VCSS is not
normally distributed). The VCSS at 6 weeks post randomisation and baseline is summarised using box plots
for both groups (see Figure 11).
Markers for clinical success: clinical, aetiological, anatomical and pathophysiological
The change in clinical classification in the CEAP score from baseline to 6 weeks post randomisation is
reported (see Table 17) and the chi-squared test was used to compare the two groups.
Safety data
The safety data, including AEs and SAEs, were provided in a tabular format for the two groups [for details,
see the statistical analysis plan on the project web page: www.journalslibrary.nihr.ac.uk/programmes/hta/
11129197/#/ (accessed 18 April 2019)]. AEs were summarised by description and outcome and SAEs were
summarised by SAE reason, frequency, severity, relationship to treatment, outcome and expectedness.
Sensitivity analysis
As a sensitivity analysis, a per-protocol analysis was performed by excluding participants with protocol
deviations. This sensitivity analysis covered all primary and secondary outcomes.
Missing data
There was no imputation of missing data for the primary end point (time to healing) or the secondary end
points of 24-week healing rate and ulcer-free time. However, multiple imputation of the quality-of-life
measures and measures of clinical success was performed using chained equations as a sensitivity
analysis.60 The number of missing data were reported.
Health economic analysis
Overview of within-trial economic analysis
The within-trial health economic analysis compared early endovenous ablation with deferred endovenous
ablation for superficial venous truncal reflux in patients with venous ulceration, within the 1-year time
horizon of the clinical trial. A cost–utility analysis was performed. No subgroup analyses were undertaken.
The analyses were performed from the perspective of the NHS and Personal Social Services in accordance
with NICE methods guidance.61
The total cost per patient aimed to include only items related to the endovenous ablation procedure or
venous leg ulcer. The price year was 2015/16. No discounting was applied as the follow-up is 1 year.
The trial was reported in accordance with guidelines for economic evaluation.62 See Husereau et al.62
for the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist and the project
web page [www.journalslibrary.nihr.ac.uk/programmes/hta/11129197/#/ (accessed 18 April 2019)] for the
health economic plan.
Data
Data were collected in the CRF by case note review and from questionnaires. The primary outcome
measure was the quality-adjusted life-years (QALYs) gained at 1 year. Health state utilities were calculated
from the EQ-5D-5L questionnaire administered to participants at baseline, and at 6 weeks and 6 and
12 months post randomisation. The base-case economic analysis uses the crosswalk tariff.63 This is an
algorithm that maps the EQ-5D-5L responses to the three-level responses and then values those health
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states using the original EQ-5D-3L tariff developed by Dolan.64 This tariff was available from the EuroQol
group and was recommended by NICE at the time of these analyses.65 As a sensitivity analysis, an
alternative five-level tariff recommended by Devlin et al.55 was used. QALYs were estimated for each
participant to 1 year as the ‘area under the curve’ of EQ-5D-5L index values.
Resource use items were recorded for each participant at monthly follow-up telephone calls. The health-
care resource use collected in the trial and the assumptions made in the economic analysis are presented
in Table 4.
TABLE 4 Resource use items collected in the trial and assumptions made in the analysis
Resource use Description
Trial vein ablation procedures Time in operating theatre and the type of procedure (UGFS, RFA, EVLA or MOCA)
were recorded. Participants could have more than one trial vein ablation procedure.
Staff procedure costs were calculated from the time in operating theatre (recorded in
the CRF) multiplied by standard unit costs (see Appendix 6)
Dressings and bandages for
wound healing
Dressings: classified in the CRF as NA dressing, Inadine™ [Systagenix (KCI company),
San Antonio, TX, USA] (iodine impregnated), or other. For estimating costs, it was
assumed that dressings were changed twice per week until wound healing
Compression: the CRF recorded if the participant used compression bandages,
stockings or no compression. If bandages, it was assumed that these were changed at
each dressing change. Participants who used compression stockings were assumed to
own two pairs (one to wash and one to wear), and that both were replaced every
3 months (Karen Dhillon, Imperial College London, 2017, personal communication).
Bandages were assumed to have been used if the CRF did not state which mode of
compression was applied (as these are the most common type of compression therapy
in use)
Compression therapy to prevent
recurrence after wound healing
The costs of compression therapy post healing were estimated in line with local policy.
For estimating costs, it was assumed that stockings were changed every 3 months
(Karen Dhillon, personal communication)
Visits to a district nurse or
primary care nurse
All these visits, for any reason, were included in the total cost
Visits from a district nurse All these visits, for any reason, were included in the total cost
Hospital admissions (inpatient
and day case)
The trial collected data on the reason for the admission and any procedure undertaken
as free text. Admissions were classified as ‘vein related’ if one of the text fields
included one of these keyword fragments: ‘leg ulcer, vein, rf, abla, evlt, evla, sclero,
screlo, vnus, foam, ugfs, angio, rehab, physio, conval, skin, antibio, sepsis, septic,
infection, dvt’ (the list takes account of spelling errors in the text field). Vein ablation
procedures were identified if one of the text fields included one of the following
keywords: ‘vein, rf, abla, evlt, evla, sclero, screlo, vnus, foam, ugfs’. Admissions were
cross-checked against protocol ablations so as not to double count the same event.
The exact date of the admission was not recorded in the admissions CRF, only the
month after randomisation. It was assumed that if two vein ablation procedures
occurred in the same month, then they were duplicate records
Outpatient visits Outpatient visits were recorded, along with free text indicating the reason for the
consultation and any procedure undertaken. Outpatient visits were classified as ‘not
vein related’ if the reason for the consultation or the procedure contained one of these
keywords: ‘tia, hernia, aaa, asth, aneurysm, ankle, opthal, arthritis, breast, bowel,
bereavement, eye, breath, carpal, cpap, cancer, chest, colorectal, diab, diet, head, ent,
endoscopy, endocrin, fall, fracture, gynae, gastro, heamat, hearing, heart, hyperdermic,
immo, testic, kidney, knee, lung, lymph, facial, nasal, oncol, ortha, ortho, urology,
pacemaker, parkinson, pessary, cateract, rheuma, renal, respiratory, reveal, recell,
rhemat, spinal, sleep, wrist, thumb, shoulder, abdo, aorta, deaf, memory, migrane,
ovary’ (note that ReCell and REVEAL are other concurrent clinical trials66,67)
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Ulcer-related health-care use
The participants in this trial tended to be elderly with comorbidities and, therefore, significant users of
health-care resources. To obtain a precise estimate of the effect of the intervention on health-care use,
and avoid statistical ‘noise’, the trial aimed to include only resource use related to the ulcer. The trial CRF
collected the reason for the use of health-care resources and the procedure undertaken as free text.
Keywords indicating ulcer-related activity included ulcer care, skin care, leg care, venous procedures,
angiography, infection, rehabilitation, DVT and related keywords (see Table 4). Ulcer-related health care
was included in the total cost per patient, whereas non-ulcer-related health care was tabulated but not
included in total cost. Non-ulcer-related care was excluded from inpatient admissions, day case admissions
and outpatient consultations. These health-care resources and costs, along with out-of-pocket expenses
and time lost from usual activities, were tabulated but not included in the total mean cost per patient.
It was assumed that all district nurse visits, primary care visits, physiotherapy and occupational therapy
were definitely or probably ulcer related.
Unit costs
Costs were estimated by multiplying resource use by unit costs obtained from published literature,
England and Wales Healthcare Resource Group costs and manufacturers’ list prices for catheters and other
disposable kit (see Appendix 6).
Handling of missing data
A small number of trial data were missing because of withdrawal or for other reasons. The extent and
pattern of missing data were assessed. Costs and EQ-5D-5L index were set to zero after the date of death.
TABLE 4 Resource use items collected in the trial and assumptions made in the analysis (continued )
Resource use Description
Vein procedures in outpatients were identified if one of the text fields included one of
the following keywords: ‘sclero, foam, ugfs’
Outpatient visits were cross-checked against protocol ablations so as not to double
count the same event. The exact date of the outpatient consultation was not recorded
in the CRF, only the month after randomisation. It was assumed that if two vein
ablation procedures occurred in the same month, then they were duplicate records
Visits to and from the GP All these visits were included in the total cost, for any reason
Use of antiplatelet and
anticoagulant medicines
The CRF recorded the drug used each month, but did not record the dose. It was
assumed that doses (taking account age, sex and weight) were as recommended by
the British National Formulary68
Physiotherapy and occupational
therapy
All these visits, for any reason, were included in the total cost
Home care visits (auxiliary
nursing)
All these visits, for any reason, were included in the total cost
Home help visits for (personal
care)
All these visits, for any reason, were included in the total cost
Out-of-pocket, informal care and
personal expenses
Time lost from work and normal activities, informal care and whether or not out-of-pocket
expenses were incurred were recorded in the CRF. These were tabulated but not included
in the NHS and Personal Social Services total costs
NA, non-adherent; REVEAL, Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification.
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For the cost-effectiveness analysis, the base case uses ‘complete cases’ in an ITT analysis. A participant was
considered to be a complete case if he or she completed all the EQ-5D questions at baseline, 6 weeks,
6 months and 1 year, and did not withdraw from the trial before 1 year.
As a sensitivity analysis, multiple imputation using chained equations was used to impute the remaining
missing data by regression, under the assumption of ‘missingness at random’.60 This means that missing
costs are considered predictable from observed data, plus or minus a random error. For each participant
lost to follow-up, costs were imputed at each month after the time of withdrawal and the EQ-5D-5L
index was imputed at 6 weeks, 6 months and 1 year if these data were missing. Ten imputed data sets
were created and analysed using Rubin’s rules (this was sufficient to give stable results allowing for
Monte Carlo error).60
Handling of protocol deviations
In the clinical trial, protocol deviations were seen in 117 patients (59 and 58 in early and deferred groups,
respectively), the majority of which were late or missed follow-up appointments (n/N = 40/59 patients in the
early-intervention group and n/N = 34/58 in the deferred-intervention group). A sensitivity analysis was
carried out excluding these participants.
Cost-effectiveness analysis
The difference in mean total costs and mean total QALYs per participant between the treatment groups
was estimated using bivariate normal regression (seemingly unrelated regression using the Stata command
‘surreg’), including baseline EQ-5D-5L in the QALY regression.69
The incremental cost-effectiveness ratio (ICER) was calculated. The probability that early ablation was more
cost-effective than deferred ablation was estimated at different cost-effectiveness thresholds using two
methods. The first method assumed bivariate normality in the distribution of total costs and QALYs. The
second method used the bootstrapping method, with 1000 Monte Carlo resamples. The bootstrap was
used only for the analysis of complete cases. Bootstrap combined with multiple imputation can be very
computationally demanding. If 1000 bootstrap resamples were used with 10 multiple imputations,
10,000 data sets would need to be generated and analysed.70
Sensitivity analyses
Five models were estimated: (1) base case – complete cases with bootstrap standard errors (SEs) and crosswalk
EQ-5D tariff; (2) complete case with bivariate normal SEs and crosswalk EQ-5D tariff; (3) multiple imputation
with bivariate normal SEs and crosswalk EQ-5D tariff; (4) complete case with bootstrap SEs and EQ-5D-5L tariff
estimated by Devlin et al.;55 and (5) as model 1, excluding participants with protocol deviations.
Database and data processing
InForm database
Data were collected and managed using InForm, an electronic data capture system built around an Oracle
database. The InForm system includes automated range checks and validation rules for data entry to help
ensure data accuracy. A computer-generated audit trail is in place, which records the date, time, operator,
operation and previous value of all manipulation of clinical data.
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InForm storage and management was undertaken by the Imperial College London information and
communication technologies team. InForm sits on a server behind a firewall connected to the college storage
area network. The data are backed up regularly to removable media, allowing for disaster recovery. In
addition to the college backup facility, every 20 minutes the activity logs for the trial are moved to another
server in a different location to facilitate rapid recovery of data, should it become necessary (e.g. in a disaster
recovery scenario).
Data were entered remotely into the database by research nurses at each site. Access to InForm is web
based with role- and site-based security applied.
Data queries
During the recruitment and follow-up phases, inconsistent, implausible or missing data were investigated
by the trial manager and further validation checks were carried out periodically by the trial statistician.
The trial manager performed quality control checks on the first two CRFs and participant questionnaires
entered at each site to ensure the accuracy of data input and that data entry processes had been understood.
Ongoing data checks using source data verification were performed at each monitoring visit as per the EVRA
monitoring plan. Missing forms and data were flagged by the trial manager periodically and distributed to the
appropriate sites on a regular basis.
Data cleaning
The data cleaning process included the following:
l ensuring that missing/unknown values are labelled accurately
l further ensuring that spurious values have not been included into data fields
l check of inconsistencies in data not flagged by inbuilt edit checks
l review of 100% of comments by the trial manager
l review of 100% of anonymised duplex reports by the chief investigator assisted by the trial manager,
to ensure that they were entered into InForm correctly
l review of 100% of the data for the primary end point, final ulcer healing date, by an independent trial
manager, to ensure that they were entered into InForm correctly.
Final data checks were performed by the statistician once the database had been soft locked before hard
lock was complete. All outstanding queries were resolved prior to the database hard lock.
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Chapter 3 Clinical results
Screening and recruitment
Recruitment commenced in October 2013 and was completed at the end of September 2016. In total,
6555 patients were screened for potential inclusion in the trial and, of these, 450 (6.9%) were randomised.
The reasons for exclusion are presented in the Consolidated Standards of Reporting Trials (CONSORT)
diagram (Figure 3).
Total number screened
(n = 6555)
Excluded, n = 6105
• Declined to participate, n = 434
• ABPI of < 0.8/arterial ulcer, n = 873
• Clinician decision, n = 496
• Ulcer duration of > 6 months, n = 1772
• Deep-venous occlusive disease precluding
   intervention, n = 199
• Does not tolerate compression, n = 35
• Superficial venous disease not significant
   enough to warrant ablation, n = 267
• Not an ulcer, n = 568
• No venous disease, n = 378
• Other, n = 9
• Other ulcer: dermatological/diabetic foot/
   mixed, n = 393
• Ulcer healed by the time of randomisation,
   n = 610
• Participant unable to consent, n = 71
Allocated to standard treatment
(n = 226)
Allocated to EVRA
(n = 224)
Allocation
Randomised
(n = 450)
Enrolment
• Withdrawal, n = 1
• Lost to follow-up, n = 1
• Withdrawal, n = 1
Follow-up to week 6
• Withdrawal, n = 6
• Death, n = 3
• Lost to follow-up, n = 2
• Inability/failure to comply with protocol, n = 1
• Withdrawal, n = 5
• Death, n = 2
• Lost to follow-up, n = 3
Follow-up to month 6
• Withdrawal, n = 10
• Death, n = 8
• Lost to follow-up, n = 5
• Inability/failure to comply with protocol, n = 1
• Withdrawal, n = 5
• Death, n = 4
• Lost to follow-up, n = 10
Follow-up to month 12
ITT, n = 226
Per-protocol analysis, n = 195
   • Protocol deviation of treatment, n = 31
ITT, n = 224
Per-protocol analysis, n = 192
  • Protocol deviation of treatment, n = 32
Analysis
FIGURE 3 Consolidated Standards of Reporting Trials diagram of the trial population. The cumulative number of
participants who had withdrawn, died, had failed to comply with the protocol or had been lost to follow-up by each
time point are presented. Reproduced from The New England Journal of Medicine, Gohel et al.57 A randomized trial
of early endovenous ablation in venous ulceration, vol. 378, pp. 2105–14. Copyright © 2018 Massachusetts Medical
Society. Reprinted with permission.
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Trial site recruitment
Ten sites were initially activated for recruitment, with a further 11 sites activated as it became apparent
that the original sites would be unable to reach their recruitment targets. Over the recruitment period,
21 sites participated in the trial, with one site failing to recruit any participants.
Appendix 7 shows the total number of participants recruited per site in order of the total number of weeks
recruiting. The first six sites opened benefited from a dedicated part-time research nurse, whereas the remaining
sites were supported by Clinical Research Network or local research nurses working across multiple studies.
Appendix 8 details the overall recruitment per month against the targets. At trial commencement, the
monthly target recruitment was 24 participants per month. When it became apparent that this was not
achievable (October 2015), the target was reduced to 13 participants per month, adding an additional
8 months to the recruitment period. The target of 450 participants was achieved on 30 September 2016.
Follow-up
Follow-up of the last recruited participant was competed on 28 September 2017. A total of 407 participants
attended the 12-month follow-up and the median follow-up period for both the deferred- and early-ablation
groups was 365 (IQR 364–370) days. Figure 3 details the trial exit time points. The cumulative numbers of
participants who had withdrawn, died, failed to comply with the protocol or been lost to follow-up by each
time point are presented.
Ineligible participants
Six ineligible participants were randomised to the trial: two participants in the early-ablation group
(one with leg ulceration of > 6 months’ duration and one with no active ulceration) and four participants
in the deferred-ablation group (two participants with leg ulceration of > 6 months’ duration, one
participant with no active leg ulceration and one participant with deep-venous occlusive disease). These
participants were included in the ITT analysis but excluded from the per-protocol analysis (see Figure 3).
Baseline characteristics of participants by trial group
The baseline characteristics, medical history, current medication, ulcer history and baseline compression
therapy are summarised in Tables 5–7. The two trial groups were well matched in terms of baseline
characteristics, including the following potential prognostic factors: ulcer duration, ulcer size, participant
age and history of DVT.
Slightly more men than women were randomised (55% vs. 45%). The mean participant BMI was 30.3 kg/m2
(clinically obese).
The baseline ulcer characteristics are summarised in Table 8. Ulcer duration was slightly greater in participants
randomised to early ablation [median 3.2 months (IQR 2.3–4.2 months)] than in the deferred-ablation group
[median 3.0 months (IQR 1.7–4.2 months)]. The median ulcer size in the early-ablation group was 2.4 cm2
(IQR 1.0–7.1 cm2), compared with 2.9 cm2 (IQR 1.1–8.2 cm2) in the deferred-ablation group.
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TABLE 5 Baseline characteristics between the early and deferred ablation group
Characteristic Early (N= 224) Deferred (N= 226) Total (N= 450)
Age (years), mean (SD) 67.0 (15.5), n = 224 68.9 (14.0), n = 226 68.0 (14.8), n = 450
Height (cm), mean (SD) 171.9 (11.1), n = 220 170.5 (10.8), n = 220 171.2 (11.0), n = 440
Weight (kg), mean (SD) 89.5 (25.6), n = 218 88.8 (24.1), n = 219 89.1 (24.9), n = 437
BMI (kg/m2), mean (SD) 30.1 (7.8), n = 218 30.4 (7.4), n = 219 30.3 (7.6), n = 437
Sex, n (%)
Female 97 (43.3) 106 (46.9) 203 (45.1)
Male 127 (56.7) 120 (53.1) 247 (54.9)
Smoking, n (%)
Current 23 (10.3) 19 (8.4) 42 (9.3)
Former 86 (38.4) 101 (44.7) 187 (41.6)
Never 115 (51.3) 106 (46.9) 221 (49.1)
Ethnicity, n (%)
White 206 (92.0) 208 (92.0) 414 (92.0)
Mixed 1 (0.4) 0 (0.0) 1 (0.2)
Asian 11 (4.9) 12 (5.3) 23 (5.1)
Black 3 (1.3) 5 (2.2) 9 (1.8)
Other 3 (1.3) 1 (0.4) 4 (0.9)
EQ-5D, mean (SD)
Health state score 70.2 (17.7), n = 222 70.1 (17.1), n = 225 70.2 (17.4), n = 447
Index value 0.7 (0.2), n = 222 0.7 (0.2), n = 226 0.7 (0.2), n = 448
SF-36, mean (SD)
Physical function 37.3 (12.0), n = 223 37.5 (12.5), n = 225 37.4 (12.2), n = 448
Role-physical 39.0 (12.2), n = 223 39.7 (12.1), n = 224 39.4 (12.2), n = 447
Body pain 41.3 (11.1), n = 223 41.6 (11.9), n = 224 41.4 (11.5), n = 447
General health 45.8 (9.2), n = 223 46.0 (9.8), n = 225 45.8 (9.5), n = 448
Vitality 48.2 (10.2), n = 222 47.8 (10.6), n = 224 48.0 (10.4), n = 446
Social functioning 42.6 (12.4), n = 223 42.4 (13.5), n = 224 42.5 (13.0), n = 447
Role-emotional 42.7 (13.8), n = 222 43.7 (13.6), n = 224 43.2 (13.7), n = 446
Mental health 49.2 (10.3), n = 222 49.3 (10.7), n = 224 49.2 (10.5), n = 446
Physical component summary 38.5 (9.9), n = 222 38.8 (10.8), n = 223 38.6 (10.4), n = 445
Mental component summary 49.2 (10.9), n = 222 49.4 (11.6), n = 223 49.3 (11.2), n = 445
Total AVVQ, mean (SD) 44.1 (9.0), n = 200 44.3 (8.7), n = 192 44.2 (8.8), n = 392
Reproduced from The New England Journal of Medicine, Gohel et al.57 A randomized trial of early endovenous ablation in
venous ulceration, vol. 378, pp. 2105–14. Copyright © 2018 Massachusetts Medical Society. Reprinted with permission.
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TABLE 6 Summary of medical history and concurrent medication
Variable Early (N= 224) Deferred (N= 226) Total (N= 450)
Previous pregnancy, n (%)a
Yes 85 (87.6) 91 (85.9) 172 (86.7)
History of DVT in pregnancy (yes) 1 (1.2) 2 (2.2) 3 (1.7)
No 12 (12.4) 15 (14.) 27 (13.3)
Hormone therapy, n (%)a
None 66 (29.5) 71 (31.4) 137 (30.4)
Previous HRT 16 (7.1) 15 (6.6) 31 (6.9)
Current HRT 1 (0.4) 3 (1.3) 4 (0.9)
Previous OC 21 (9.4) 21 (9.3) 42 (9.3)
Current OC 2 (0.9) 1 (0.4) 3 (0.7)
Previous rheumatoid disease, n (%)
No 204 (91.1) 212 (93.8) 416 (92.4)
Yes 20 (8.9) 14 (6.2) 34 (7.6)
Previous DVT in either leg, n (%)
No 206 (92.0) 203 (89.8) 409 (90.9)
Yes 18 (8.0) 23 (10.2) 41 (9.1)
Previous DVT in trial leg, n (%)
No 206 (93.3) 203 (93.4) 409 (93.2)
Yes 15 (6.7) 15 (6.6) 30 (6.8)
Current antiplatelet therapy, n (%)
None 172 (76.8) 179 (79.2) 351 (78.0)
Aspirin 49 (21.9) 44 (19.5) 93 (20.7)
Clopidogrel 5 (2.2) 5 (2.2) 10 (2.2)
Other 1 (0.4) 0 (0) 1 (0.2)
Current anticoagulation therapy, n (%)
None 196 (87.5) 189 (83.6) 385 (85.6)
Warfarin 25 (11.2) 32 (14.2) 57 (12.7)
New oral anticoagulants 2 (0.9) 4 (1.8) 6 (1.3)
Other 1 (0.4) 1 (0.4) 2 (0.4)
Current steroids, n (%)
No 211 (94.2) 220 (97.4) 431 (95.8)
Yes 13 (5.8) 6 (2.7) 19 (4.2)
Current trental (pentoxifylline), n (%)
No 224 (100) 226 (100) 450 (100)
Yes 0 (0) 0 (0) 0 (0)
Diabetes, n (%)
No 190 (84.8) 198 (87.6) 388 (86.2)
Yes 34 (15.2) 28 (12.4) 62 (13.8)
HRT, hormone replacement therapy; OC, oral contraception.
a Female only.
Reproduced from The New England Journal of Medicine, Gohel et al.57 A randomized trial of early endovenous ablation in
venous ulceration, vol. 378, pp. 2105–14. Copyright © 2018 Massachusetts Medical Society. Reprinted with permission.
CLINICAL RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
28
TABLE 7 Summary of ulcer history and baseline compression
Variable Early (N= 224) Deferred (N= 226)
Previous ulcer (yes), n (%)
No 106 (47.3) 108 (48.0)
Yes 118 (52.7) 117 (52.0)
Ulcer dressing, n (%)
NA 64 (28.6) 55 (24.3)
Inadine 28 (12.5) 25 (11.1)
Other 131 (58.5) 146 (64.6)
Missing 1 (0.4) 0 (0)
Baseline compression, n (%)
Nonea 3 (1.3) 7 (3.1)
KTwo (Urgo Limited, Loughborough, UK) 32 (14.3) 29 (12.8)
Three-layer bandage 42 (18.8) 41 (18.1)
Four-layer bandage 59 (26.3) 59 (26.1)
European short stretch 43 (19.2) 36 (15.9)
Stocking, n (%) 42 (18.8) 53 (23.5)
Other 2 (0.9) 1 (0.4)
Missing 1 (0.4) 0 (0)
Time of wearing, n (%)
Day and night 196 (87.5) 185 (81.9)
Day only 25 (11.2) 39 (17.3)
Missing 3 (1.3) 2 (0.9)
NA, non-adherent.
a For participants not treated with compression at baseline, compression therapy was commenced at randomisation.
Reproduced from The New England Journal of Medicine, Gohel et al.57 A randomized trial of early endovenous ablation in
venous ulceration, vol. 378, pp. 2105–14. Copyright © 2018 Massachusetts Medical Society. Reprinted with permission.
TABLE 8 Characteristics of current ulcer
Characteristic Early (N= 224) Deferred (N= 226)
Ulcer duration (months), median (IQR)a 3.2 (2.3–4.2) 3.0 (1.7–4.2)
Trial ulcer leg, n (%)
Right 107 (47.8) 115 (50.9)
Left 117 (52.2) 111 (49.1)
Ulcer location, n (%)
Lateral 92 (41.1) 93 (41.2)
Medial 116 (51.8) 118 (52.2)
Circumferential 9 (4.0) 7 (3.1)
Missing 7 (3.1) 8 (3.5)
Ulcer size (cm2), median (IQR)b 2.4 (1.0–7.1) 2.9 (1.1–8.2)
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The six ineligible participants included two participants who had a healed ulcer at the time of randomisation
(which was confirmed after randomisation). The ineligible participant with deep-venous occlusive disease
was confirmed to have both deep vein reflux and outflow obstruction by baseline duplex ultrasonography
scan. In general, ulcer characteristics were well matched between the two groups.
Table 9 details the patterns of superficial truncal venous reflux at baseline.
TABLE 8 Characteristics of current ulcer (continued )
Characteristic Early (N= 224) Deferred (N= 226)
Duplex ultrasound scan: deep vein, n (%)
Normal 150 (67.0) 157 (69.5)
Abnormalc 74 (33.0) 69 (30.5)
Reflux 74 (100) 69 (100)
Outflow obstruction 0 (0) 0 (0)
CEAP score: clinical signs – grade, n (%)
C5 1 (0.4) 1 (0.4)
C6 224 (99.6) 225 (99.6)
CEAP score: clinical signs – presentation, n (%)
Asymptomatic 0 (0) 0 (0)
Symptomatic 224 (100) 226 (100)
Aetiological classification, n (%)
Primary 217 (96.9) 214 (94.7)
Secondary 7 (3.1) 12 (5.3)
Deep 0 (0) 0 (0)
No venous cause 0 (0) 0 (0)
Anatomical distribution, n (%)
Superficial 220 (98.2) 221 (97.8)
Perforator 3 (1.3) 3 (1.3)
Deep 1 (0.4) 2 (0.9)
Pathophysiological dysfunction, n (%)
Reflux 224 (100) 226 (100)
Obstruction 0 (0) 0 (0)
Both 0 (0) 1 (0.4)
No venous cause 0 (0) 0 (0)
VCSS, median (IQR) 15 (14–18) 16 (14–18)
Palpable pedal pulses, n (%)
No 15 (6.7) 14 (6.2)
Yes 209 (93.3) 212 (93.8)
a Ulcer duration as reported by participant.
b Ulcer size evaluated using digital planimetry from standardised digital photographs by assessor blinded to
intervention group.
c Defined as presence of retrograde flow in common femoral, femoral or popliteal veins of > 1-second duration after
augmentation. A participant can have both deep vein reflux and obstruction.
Reproduced from The New England Journal of Medicine, Gohel et al.57 A randomized trial of early endovenous ablation in
venous ulceration, vol. 378, pp. 2105–14. Copyright © 2018 Massachusetts Medical Society. Reprinted with permission.
CLINICAL RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
30
Interventions
Ablation method and timing of the first ablation are summarised in Table 10. There were 55 participants
who did not undergo ablation in the deferred-intervention group and seven in the early-ablation group,
including one in whom the procedure was abandoned before completion. The most common intervention
was UGFS alone (47%), followed by endothermal ablation alone (29%).
Among the 55 participants in the deferred-ablation group who did not undergo endovenous ablation up
to 1 year, 19 participants died, withdrew or were lost to follow-up from the trial and 36 participants
completed the trial, including 27 participants with healed ulcer and nine participants with unhealed ulcer
at 1 year (Table 11).
TABLE 9 Summary of truncal venous reflux patterns at baseline
Pattern of superficial reflux at baseline Early (N= 224), n (%) Deferred (N= 226), n (%)
GSV reflux alone 123 (54.9) 125 (55.4)
SSV reflux alone 25 (11.2) 30 (13.3)
GSV and SSV reflux 65 (29.0) 56 (24.8)
Other pattern of refluxa 11 (4.9) 15 (6.6)
GSV, great saphenous vein; SSV, short saphenous vein.
a Accessory saphenous, perforator vein or tributary vein reflux.
Reproduced from The New England Journal of Medicine, Gohel et al.57 A randomized trial of early endovenous ablation in
venous ulceration, vol. 378, pp. 2105–14. Copyright © 2018 Massachusetts Medical Society. Reprinted with permission.
TABLE 10 Summary of endovenous ablation procedures performed
Variable Early (N= 224) Deferred (N= 226)
Interventional ablation type, n (%)
No ablation 6 (2.7) 55 (24.3)
Endothermal onlya 71 (31.7) 54 (23.9)
UGFS onlyb 111 (49.6) 100 (44.3)
MOCA only 5 (2.2) 1 (0.4)
Endothermala and UGFSb 27 (12.1) 16 (7.1)
MOCA and UGFSb 3 (1.3) 0 (0)
Abandoned ablation 1 (0.5) 0 (0)
Timing of first ablation procedure,c n (%)
No ablation 6 (2.7) 55 (24.3)d
Within 2 weeks 203 (90.6) 1 (0.4)
Before ulcer healing 200 1e
After ulcer healing 3 0
Between 2 and 4 weeks 9 (4.0) 1 (0.4)
Before ulcer healing 9 1e
After ulcer healing 0 0
continued
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Regarding the timing of ablation, the majority of participants (90.6%) in the early-ablation group underwent
ablation within 2 weeks of randomisation. In the deferred-ablation group, one participant was treated
before 2 weeks and five participants were treated prior to ulcer healing between 2 weeks and 6 months.
The reasons for the ablation before ulcer healing in the six participants in the deferred-ablation group were
clinical deterioration of ulcer (n = 3), participant request for intervention (participant unwilling to continue
with deferred ablation strategy) (n = 2) and participant treated early in error (n = 1).
TABLE 10 Summary of endovenous ablation procedures performed (continued )
Variable Early (N= 224) Deferred (N= 226)
Between 4 weeks and 6 months 6 (2.7) 103 (45.6)
Before ulcer healing 4 4e
After ulcer healing 2 99
After 6 months 0 (0) 66 (29.2)
Before ulcer healing 0 19
After ulcer healing 0 47
a Endovenous thermal ablation procedures included laser and radiofrequency ablation.
b UGFS to treat tributary veins or subulcer venous plexus performed as per the standard technique of the treating clinician.
c Timing of first endovenous ablation only. Timing of any additional ablations was left to the discretion of treating clinicians.
d Among the 55/226 (24.3%) participants in the deferred-ablation group who were not treated by 12 months post
randomisation, the ulcer was healed in 27 and not healed in nine; the remaining 19 participants had either died (n = 7),
withdrawn (n = 7) or were lost to follow-up (n = 5). Among the 27 participants with healed ulcers, 16 participants
declined ablation, three were no longer deemed to be suitable for ablation (as decided by the treating clinician), six were
on the waiting list for ablation and may have been treated after 12 months; in the case of the remaining two
participants, the reasons for not receiving ablation are unclear.
e Reasons for ablation before ulcer healing in six participants in the deferred-ablation group were clinical deterioration
of ulcer (n = 3), participant request for ablation (unwilling to continue with deferred ablation strategy) (n = 2) and
participant treated early in error (n = 1).
Reproduced from The New England Journal of Medicine, Gohel et al.57 A randomized trial of early endovenous ablation in
venous ulceration, vol. 378, pp. 2105–14. Copyright © 2018 Massachusetts Medical Society. Reprinted with permission.
TABLE 11 Summary of participants not having endovenous ablation
Completion of the trial Deferred (N= 55) Early (N= 6)
Yes, n (%) 36 (65.5) 2 (33.3)
Ulcer healed by 12 months 27 2
Ulcer not healed by 12 months 9 0
No, n (%) 19 (34.5) 4 (66.7)
Withdrawal 7 3
Death 7 1
Other 5 0
Reproduced from The New England Journal of Medicine, Gohel et al.57 A randomized trial of early endovenous ablation in
venous ulceration, vol. 378, pp. 2105–14. Copyright © 2018 Massachusetts Medical Society. Reprinted with permission.
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Primary outcome: ulcer healing
Figure 4 shows the KM curve for time to ulcer healing. Among the 450 participants were two ineligible
participants whose ulcer had healed by the time of randomisation and who did not contribute to the
survival analysis. The median healing time was 56 (95% CI 49 to 66) days and 82 (95% CI 69 to 92) days
in the early- and deferred-ablation groups, respectively.
The proportional hazards assumption, assessed graphically, by plotting –ln{–ln[Sˆ(t)]} versus –ln(t), and
numerically, using Grambsch and Therneau tests, was not violated.
Table 12 shows the Cox proportional hazards regression results. In the univariate model, with trial centre
as a random effect, the hazard ratio (HR) for ulcer healing in the early-ablation group is 1.38 (95% CI 1.13
to 1.68) (p = 0.001) compared with participants randomised to deferred ablation. After further adjusting
for age, ulcer duration and ulcer size at baseline, the HR is 1.42 (95% CI 1.16 to 1.73) (p = 0.001).
The HRs from the multivariable Cox regression model for specific (pre-planned) subgroups are presented
in Figure 5. There is considerable consistency except for ulcer duration, where an interesting trend is
observed. In the prespecified subgroup analysis to investigate any differential treatment effects of ulcer
duration, the HR in the early ablation group increases across the quartiles of ulcer duration. In the first and
second quartiles of ulcer duration, early ablation does not make a difference to ulcer healing relative to
deferred ablation. However, this study is not powered to investigate any interactions and thus the above
finding will need further studies to confirm.
Figure 6 shows the HRs for different treatments in the early ablation group compared with deferred
ablation. As numbers in the MOCA only group, endothermal and UGFS group, and MOCA and UGFS
group are small, the three ablation groups are merged into one group as ‘other ablation’. The HRs for the
groups of endothermal only, UGFS only and other treatment are consistent.
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FIGURE 4 Kaplan–Meier curve showing ulcer healing time in the early- and deferred-ablation groups (p= 0.001,
log-rank test). Ulcer healing rates were greater in participants randomised to early ablation. Reproduced from
The New England Journal of Medicine, Gohel et al.57 A randomized trial of early endovenous ablation in venous
ulceration, vol. 378, pp. 2105–14. Copyright © 2018 Massachusetts Medical Society. Reprinted with permission.
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Secondary outcomes
Ulcer-free time to 1 year
Of the 450 participants, 407 attended the 12-month follow-up visit and were included in the analysis of
ulcer-free time to 1 year. There were 203 and 204 participants in the deferred- and early-ablation groups,
respectively. The median ulcer-free time to 1 year was 278 (IQR 175–324) days and 306 (IQR 240–328)
days in the deferred- and early-ablation groups, respectively.
As the ulcer-free time to 1 year did not follow a normal distribution and mathematical transformation was
not possible because of a few participants with zero days ulcer-free time, ulcer-free time to 1 year was
categorised (into quartiles) and ordinal regression was used to assess the difference between the treatment
groups. The proportionality assumption was not violated (assessed using the Brant test). The results are
presented in Table 13. In the univariable analysis, with trial centre as a random effect, the odds ratio (OR)
for being in a higher quartile was 1.60 (95% CI 1.13 to 2.27) for the early-ablation group. Further adjustment
for age, ulcer duration and size at baseline did not affect the result. The OR in the multivariable model is
1.54 (95% CI 1.07 to 2.21; p = 0.02).
Figure 7 shows the results of ordinal logistic regression in different subgroups. The results are consistent
across different subgroups. The pattern observed is similar to that seen in the subgroup analysis by ulcer
size and duration.
Figure 8 shows the ORs for the treatment effect on ulcer-free time by type of endovenous ablation.
The ORs are consistent in the groups of endothermal only and UGFS only, whereas the OR in the other
treatment group is 1.06 (95% CI 0.56 to 2.02). The lack of treatment effect here may be due to the small
number in the other treatment group.
TABLE 12 Time to ulcer healing in participants with venous ulceration (Cox regression model)
Variable Na na
Univariable modelb Multivariable modelc
HR (95% CI) p-value HR (95% CI) p-value
Treatment
Deferred group 226 194 Reference Reference
Early group 224 210 1.38 (1.13 to 1.68) 0.001 1.42 (1.16 to 1.73) 0.001
Age (years) 448 402 1.00 (0.99 to 1.00) 0.25 1.00 (0.99 to 1.01) 0.69
Ulcer duration (months)
First quartile (0.9–2.2) 113 102 Reference Reference
Second quartile (2.3–3.1) 114 101 1.01 (0.77 to 1.33) 0.96 1.00 (0.76 to 1.33) 0.97
Third quartile (3.1–4.2) 111 105 1.11 (0.85 to 1.47) 0.44 1.14 (0.86 to 1.51) 0.35
Fourth quartile (4.2–8.4) 112 96 0.75 (0.56 to 0.99) 0.04 0.79 (0.59 to 1.05) 0.10
Ulcer size (cm2)
First quartile (0.4–1.5) 113 108 Reference Reference
Second quartile (1.6–2.9) 112 108 0.79 (0.61 to 1.04) 0.09 0.72 (0.55 to 0.95) 0.02
Third quartile (3–7.5) 113 101 0.52 (0.40 to 0.69) < 0.001 0.51 (0.38 to 0.67) < 0.001
Fourth quartile (8–235) 112 87 0.31 (0.23 to 0.41) < 0.001 0.29 (0.22 to 0.39) < 0.001
a N, total number of participants; n, number of participants with healing ulcer.
b Adjusted by centre (centre included in the model as a random effect).
c Adjusted by centre, age, ulcer size and duration (centre included in the model as random effect and age, ulcer size and
duration as fixed effects).
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0.0 1.0 2.0 3.0
Deferred better Early better
BMI (kg/m2) 
   Underweight
   Normal
   Overweight
   Obese
Age (years)
   < 50
   50 – 70
   > 70
Sex
   Male
   Female
Smoker
   Never
   Current
   Former
Ulcer size (cm2)
   First quartile
   Second quartile
   Third quartile
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FIGURE 5 Forest plot of subgroup analysis for primary outcome. The healing advantage in prespecified subgroups
was consistent with the overall healing benefit observed with early ablation. The broken line indicates overall HR
for ulcer healing in entire study population. Reproduced from The New England Journal of Medicine, Gohel et al.57
A randomized trial of early endovenous ablation in venous ulceration, vol. 378, pp. 2105–14. Copyright © 2018
Massachusetts Medical Society. Reprinted with permission.
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FIGURE 6 Forest plot of different endovenous ablation techniques for primary outcome. The healing advantage in
prespecified subgroups treated with different ablation techniques was consistent with the overall healing benefit.
The broken line indicates overall HR for ulcer healing in entire study population. Reproduced from The New
England Journal of Medicine, Gohel et al.57 A randomized trial of early endovenous ablation in venous ulceration,
vol. 378, pp. 2105–14. Copyright © 2018 Massachusetts Medical Society. Reprinted with permission.
TABLE 13 Ordinal logistic regression for ulcer-free time to 1 year (quartiles) in participants with venous ulceration
Variable
Univariable modela Multivariable modelb
Coefficient (95% CI) p-value Coefficient (95% CI) p-value
Treatment group
Deferred Reference Reference
Early 1.60 (1.13 to 2.27) 0.009 1.54 (1.07 to 2.21) 0.02
Age (years) 0.99 (0.98 to 1.00) 0.14 1.00 (0.98 to 1.01) 0.57
Ulcer duration (months)
First quartile (0.9–2.2) Reference Reference
Second quartile (2.3–3.1) 0.87 (0.53 to 1.44) 0.59 0.94 (0.56 to 1.56) 0.80
Third quartile (3.1–4.2) 0.94 (0.57 to 1.55) 0.82 0.96 (0.58 to 1.60) 0.89
Fourth quartile (4.2–8.4) 0.55 (0.33 to 0.92) 0.02 0.64 (0.38 to 1.08) 0.10
Ulcer size (cm2)
First quartile (0.4–1.5) Reference Reference
Second quartile (1.6–2.9) 0.50 (0.30 to 0.82) 0.006 0.48 (0.29 to 0.79) 0.004
Third quartile (3–7.5) 0.23 (0.14 to 0.39) < 0.001 0.23 (0.14 to 0.39) < 0.001
Fourth quartile (8–235) 0.09 (0.05 to 0.16) < 0.001 0.10 (0.06 to 0.17) < 0.001
a Adjusted by centre (centre included in the model as a random effect).
b Adjusted by centre, age, duration and size (centre included in the model as random effect and age, ulcer duration and
size as fixed effects).
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FIGURE 7 Forest plot showing the treatment effect on ulcer-free time by predefined subgroups.
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Ulcer healing at 12 and 24 weeks
The unadjusted KM time-to-event ulcer healing analysis can be seen in Table 14. The healing rates at
24 weeks were higher in the early-ablation group (85.6%, 95% CI 80.6% to 89.8%) than in the deferred-
ablation group (76.3%, 95% CI 70.5% to 81.7%).
In a post hoc analysis to allow comparison with published studies, the 12-week ulcer healing rate was
63.5% (95% CI 57.2% to 69.8%) in the early-ablation group and 51.6% (95% CI 45.2% to 58.3%) in
the deferred group. A total of 404 (89.8%) of 450 randomised participants had healed by 1 year post
randomisation [210/224 (93.8%) in the early-ablation group and 194/226 (85.8%) in the deferred-ablation
group]. The absolute difference in healing rates between the groups was 7.9% (95% CI 2.3% to 13.5%).
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   Deferred arm
   Early arm: no treatment
   Early arm: endothermal alone
   Early arm: UGFS alone
   Early arm: other
Total
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FIGURE 8 Forest plot showing the treatment effect on ulcer-free time by different ablation techniques.
TABLE 14 Summary of 12- and 24-week ulcer healing rates and ulcer-free time
Variable Early (N= 224) Deferred (N= 226)
Ulcer healing ratea (95% CI) (%)
12 weeks 63.5 (57.2 to 69.8) 51.6 (45.2 to 58.3)
24 weeks 85.6 (80.6 to 89.8) 76.3 (70.5 to 81.7)
Number of participants with a healed ulcer at 12 months, n (%) 210 (93.8) 194 (85.8)
Number of participants with recurrent ulcer, n (%)b 24 (11.4) 32 (16.5)
Ulcer-free time (days), median (IQR) 306 (240–328), n = 204 278 (175–324), n = 203
a Data presented as estimation by KM curve (95% CI).
b Proportion of participants with ulcer healed at 12 months.
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Quality of life
Table 15 and Figures 9 and 10 summarise the HRQoL data at baseline, 6 weeks and 6 and 12 months for
the two trial groups. The AVVQ has scores ranging from 0 to 100, with 0 representing the best score
and 100 the worst score, whereas, for EQ-5D and SF-36, the higher the score, the better the HRQoL.
A decreasing trend of AVVQ score across time is observed for both the deferred- and early-ablation groups.
TABLE 15 Summary of quality of life (AVVQ, EQ-5D, SF-36) at baseline and at 6 weeks and 6 and 12 months after
randomisation
Variable Baseline 6 weeks 6 months 12 months p-valuea
Early, n 226 21 204 199
Deferred, n 224 219 208 203
AVVQ score, mean (SD)
Deferred 44.3 (8.7),
n = 192
41.2 (9.3),
n = 170
39.5 (10.3),
n = 140
34.3 (10.4),
n = 130
Early 44.1 (9.0),
n = 200
39.4 (10.2),
n = 176
34.6 (9.4)
n = 139
32.4 (8.3),
n = 127
Difference (95% CI)b –0.2
(–2.0 to, 1.6)
–2.1
(–4.0 to –0.2)
–4.8
(–6.9 to –2.7)
–1.8
(–4.0 to 0.3)
0.0008
EQ-5D health score, mean (SD)
Deferred 70.1 (17.1),
n = 225
71.1 (18.7),
n = 205
71.4 (19.6),
n = 193
73.7 (17.4),
n = 184
Early 70.2 (17.7),
n = 222
72.7 (18.6),
n = 212
74.1 (15.8),
n = 185
74.8 (16.9),
n = 183
Difference (95% CI)b 0.1
(–3.1 to 3.4)
1.7
(–1.6 to 5.1)
1.8
(–1.6 to 5.2)
1.3
(–2.1 to 4.8)
0.72
EQ-5D index value, mean (SD)c
Deferred 0.73 (0.2),
n = 226
0.75 (0.2),
n = 208
0.76 (0.2),
n = 192
0.80 (0.2),
n = 182
Early 0.73 (0.2),
n = 222
0.79 (0.2),
n = 211
0.81 (0.2),
n = 186
0.83 (0.2),
n = 184
Difference (95% CI)b –0.01
(–0.04 to 0.03)
0.04
(0.00 to 0.08)
0.04
(0.00 to 0.08)
0.03
(–0.01 to 0.07)
0.03
SF-36 physical function score, mean (SD)
Deferred 37.5 (12.5),
n = 225
37.4 (13.0),
n = 207
37.4 (13.7),
n = 193
38.7 (13.4),
n = 180
Early 37.3 (12.0),
n = 223
39.1 (12.7),
n = 212
39.1 (12.8),
n = 187
39.4 (12.9),
n = 182
Difference (95% CI)b –1.0
(–3.1 to 1.1)
1.0
(–1.2 to 3.1)
0.7
(–1.5 to 2.8)
0.3
(–1.9 to 2.6)
0.09
SF-36 role-physical score, mean (SD)
Deferred 39.7 (12.1),
n = 224
41.4 (12.7),
n = 207
42.4 (12.7),
n = 192
44.3 (12.9),
n = 180
Early 39.0 (12.2),
n = 223
40.3 (12.5),
n = 211
43.6 (12.6),
n = 187
43.0 (12.7),
n = 181
Difference (95% CI)b –1.3
(–3.5 to 0.9)
–1.7
(–4.0 to 0.6)
0.4
(–2.0 to 2.7)
–1.7
(–4.1 to 0.7)
0.28
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TABLE 15 Summary of quality of life (AVVQ, EQ-5D, SF-36) at baseline and at 6 weeks and 6 and 12 months after
randomisation (continued )
Variable Baseline 6 weeks 6 months 12 months p-valuea
SF-36 body pain score, mean (SD)
Deferred 41.6 (11.9),
n = 224
44.3 (12.3),
n = 207
45.9 (12.2),
n = 193
47.8 (11.2),
n = 180
Early 41.3 (11.1),
n = 223
46.6 (10.6),
n = 212
48.2 (11.0),
n = 187
49.3 (11.0),
n = 182
Difference (95% CI)b –0.5
(–2.6 to 1.6)
2.2
(0.1 to 4.4)
2.1
(–0.2 to 4.3)
1.1
(–1.1 to 3.3)
0.05
SF-36 general health score, mean (SD)
Deferred 46.0 (9.8),
n = 225
45.6 (9.2),
n = 207
44.5 (10.1),
n = 193
45.1 (10),
n = 181
Early 45.8 (9.2),
n = 223
45.7 (9.1),
n = 212
44.9 (9.8),
n = 187
45.3 (10),
n = 183
Difference (95% CI)b –0.3
(–2.0 to 1.5)
0.0
(–1.8 to 1.8)
0.0
(–1.9 to 1.8)
0.4
(–1.5 to 2.3)
0.86
SF-36 vitality score, mean (SD)
Deferred 47.8 (10.6),
n = 224
47.5 (11.3),
n = 207
48.8 (10.8),
n = 193
49.6 (9.8),
n = 179
Early 48.2 (10.2),
n = 222
49.1 (10.0),
n = 212
49.4 (9.5),
n = 187
50.5 (9.4),
n = 182
Difference (95% CI)b 0.1
(–1.7 to 2.0)
1.4
(–0.5 to 3.3)
0.0
(–1.9 to 2.0)
0.9
(–1.0 to 2.9)
0.31
SF-36 social functioning score, mean (SD)
Deferred 42.4 (13.5),
n = 224
44.0 (12.1),
n = 207
44.7 (12.5),
n = 193
47.3 (11.4),
n = 181
Early 42.6 (12.4),
n = 223
44.9 (11.6),
n = 212
47.0 (10.5),
n = 186
47.4 (10.7),
n = 182
Difference (95% CI)b –0.1
(–2.3 to 2.0)
0.6
(–1.6 to 2.8)
1.5
(–0.8 to 3.7)
–0.4
(–2.7 to 2.0)
0.40
SF-36 role-emotional score, mean (SD)
Deferred 43.7 (13.6),
n = 224
45.9 (13.3),
n = 207
45.1 (13.2),
n = 193
47.5 (12.2),
n = 179
Early 42.7 (13.8),
n = 222
46.1 (12.8),
n = 212
47.2 (12.2),
n = 187
45.9 (13.0),
n = 182
Difference (95% CI)b –1.4
(–3.8 to 1.0)
0.0
(–2.5 to 2.5)
1.7
(–0.9 to 4.2)
–1.7
(–4.3 to 0.9)
0.08
SF-36 mental health score, mean (SD)
Deferred 49.3 (10.7),
n = 224
49.2 (10.8),
n = 207
49.5 (10.4),
n = 193
50.7 (10.1),
n = 179
Early 49.2 (10.3),
n = 222
50.6 (10.4),
n = 212
51.7 (9.7),
n = 187
51.0 (9.3),
n = 182
Difference (95% CI)b –0.2
(–2.1 to 1.7)
1.3
(–0.7 to 3.2)
1.7
(–0.3 to 3.7)
–0.2
(–2.2 to 1.8)
0.07
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TABLE 15 Summary of quality of life (AVVQ, EQ-5D, SF-36) at baseline and at 6 weeks and 6 and 12 months after
randomisation (continued )
Variable Baseline 6 weeks 6 months 12 months p-valuea
SF-36 physical component summary score, mean (SD)
Deferred 38.8 (10.8),
n = 223
39.6 (11.6),
n = 207
40.4 (12.1),
n = 193
41.8 (12.0),
n = 178
Early 38.5 (9.9),
n = 222
40.4 (10.2),
n = 212
41.5 (11.5),
n = 187
42.1 (11.6),
n = 181
Difference (95% CI)b –0.8
(–2.8 to 1.1)
0.3
(–1.7 to 2.2)
0.3
(–1.7 to 2.3)
0.3
(–1.7 to 2.3)
0.41
SF-36 mental component summary score, mean (SD)
Deferred 49.4 (11.6),
n = 223
50.2 (11.0),
n = 207
50.2 (10.4),
n = 193
52.0 (10.0),
n = 178
Early 49.2 (10.9),
n = 222
51.1 (10.4),
n = 212
52.2 (9.8),
n = 187
51.6 (9.5),
n = 181
Difference (95% CI)b –0.3
(–2.2 to 1.7)
0.9
(–1.1 to 2.9)
1.5
(–0.5 to 3.6)
–0.7
(–2.7 to 1.4)
0.09
a p-value for the overall difference between the two groups over the whole trial period.
b Difference between two groups estimated using a mixed model with adjustment for time, age, ulcer duration and size as
fixed effects, with trial centre and participant as random effects. Deferred-ablation group used as reference.
c EQ-5D index calculated using the value set for England.57
Reproduced from The New England Journal of Medicine, Gohel et al.57 A randomized trial of early endovenous ablation in
venous ulceration, vol. 378, pp. 2105–14. Copyright © 2018 Massachusetts Medical Society. Reprinted with permission.
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FIGURE 9 The changes in AVVQ score over time in the early- and deferred-ablation groups.
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At baseline, AVVQ, EQ-5D-5L and SF-36 scores were similar in the early- and deferred-ablation groups.
Overall, there was a significant difference in mean AVVQ scores between the treatment groups over time
(p < 0.001), with lower mean scores, suggesting better disease-specific HRQoL, in the early-ablation group.
There was a significant difference over time in mean EQ-5D index value between the treatment groups
(p = 0.03), with more favourable scores in those randomised to early ablation, and in mean SF-36 body
pain (p = 0.05). Observed differences between the groups for the other generic HRQoL measures were
not statistically significant. However, as there was no control for multiple testing, these results should be
interpreted with caution.
Table 16 summarises the HRQoL data with multiple imputation of missing values, which produces similar
values.
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FIGURE 10 The changes in EQ-5D: (a) health score and (b) index value over time in the early- and deferred-ablation
groups.
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TABLE 16 Summary of quality-of-life outcomes with multiple imputation of missing values
Variable Baseline 6 weeks 6 months 12 months
AVVQ score, mean (SD)
Early ablation 44.0 (9.0) 39.1 (10.2) 34.9 (10.1) 33.0 (9.7)
Deferred ablation 44.2 (8.9) 41.2 (9.7) 39.4 (10.3) 34.8 (10.8)
Difference (95% CI)a –0.2 (–2.1 to 1.7) –2.2 (–4.7 to 0.3) –4.5 (–6.5 to –2.5) –1.8 (–4.1 to 0.5)
EQ-5D health score, mean (SD)
Early ablation 70.2 (17.7) 72.6 (18.7) 73.6 (16.3) 74.8 (17.5)
Deferred ablation 70.0 (17.1) 70.7 (19.1) 71.5 (19.4) 73.0 (17.8)
Difference (95% CI)a 0 (–3.3 to 3.3) 1.8 (–1.8 to 5.4) 1.8 (–2.0 to 5.7) 1.8 (–1.6 to 5.1)
EQ-5D index value, mean (SD)b
Early ablation 0.73 (0.2) 0.79 (0.2) 0.81 (0.2) 0.83 (0.2)
Deferred ablation 0.73 (0.2) 0.74 (0.2) 0.77 (0.2) 0.80 (0.2)
Difference (95% CI)a –0.01 (–0.05 to 0.03) 0.04 (0 to 0.09) 0.04 (0 to 0.08) 0.03 (–0.01 to 0.07)
SF-36 physical function score, mean (SD)
Early ablation 37.4 (12.0) 39.1 (12.9) 39.4 (12.9) 39.7 (13.3)
Deferred ablation 37.5 (12.5) 37.4 (13.0) 37.9 (13.6) 38.3 (13.7)
Difference (95% CI)a –1.0 (–3.2 to 1.1) 0.8 (–1.4 to 3.1) 0.6 (–1.7 to 3.0) 0.7 (–1.6 to 3.0)
SF-36 role-physical score, mean (SD)
Early ablation 39.1 (12.2) 40.3 (12.6) 43.6 (12.6) 43.3 (12.9)
Deferred ablation 39.7 (12.1) 41.5 (12.6) 42.6 (12.8) 43.8 (13.1)
Difference (95% CI)a –1.2 (–3.5 to 1.0) –1.9 (–4.1 to 0.4) 0.4 (–2.6 to 3.3) –0.9 (–3.4 to 1.5)
SF-36 body pain score, mean (SD)
Early ablation 41.3 (11.1) 46.6 (10.6) 48.3 (11) 49.4 (11.1)
Deferred ablation 41.6 (11.9) 44.0 (12.2) 46.1 (12) 47.5 (11.5)
Difference (95% CI)a –0.5 (–2.6 to 1.6) 2.4 (0 to 4.7) 2.1 (–0.2 to 4.4) 1.9 (–0.3 to 4.0)
SF-36 general health score, mean (SD)
Early ablation 45.8 (9.2) 45.5 (9.1) 44.8 (9.8) 45.1 (10.0)
Deferred ablation 46.0 (9.8) 45.5 (9.3) 44.7 (10.2) 44.6 (10.2)
Difference (95% CI)a –0.3 (–2.1 to 1.5) –0.1 (–1.9 to 1.8) –0.1 (–2.1 to 2.0) 0.4 (–1.4 to 2.2)
SF-36 vitality score, mean (SD)
Early ablation 48.2 (10.2) 49.0 (10.2) 49.1 (9.6) 50.2 (9.7)
Deferred ablation 47.9 (10.5) 47.4 (11.2) 48.7 (10.7) 49.0 (10.0)
Difference (95% CI)a 0.1 (–1.7 to 2.0) 1.3 (–0.6 to 3.2) 0.2 (–2.0 to 2.4) 1.0 (–0.9 to 3.0)
SF-36 social functioning score, mean (SD)
Early ablation 42.6 (12.4) 44.8 (11.6) 46.9 (10.7) 47.1 (11.0)
Deferred ablation 42.4 (13.5) 43.8 (12.1) 44.9 (12.4) 46.7 (11.7)
Difference (95% CI)a –0.1 (–2.2 to 2.1) 0.6 (–1.7 to 2.9) 1.6 (–0.9 to 4.1) 0.1 (–2.1 to 2.4)
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Clinical and technical success
Table 17 and Figure 11 show the clinical success at 6 weeks. The number of participants with improvement
of clinical grade is 72 (31.9%) and 106 (47.3%) in deferred and early ablation groups, respectively.
The VCSS evaluates changes in condition over time, with lower scores indicating better condition. Figure 11
clearly shows that early ablation was associated with a lower VCSS at week 6 than deferred ablation,
whereas the VCSS at baseline was similar in both groups.
On assessment of post-ablation duplex ultrasound scans at 6 weeks, treated segments were completely
ablated in 179 (83.3%) of 215 scanned participants and 74.8% of legs had no evidence of residual reflux.
TABLE 16 Summary of quality-of-life outcomes with multiple imputation of missing values (continued )
Variable Baseline 6 weeks 6 months 12 months
SF-36 role-emotional score, mean (SD)
Early ablation 42.7 (13.7) 46.1 (12.8) 47.0 (12.5) 45.6 (13.4)
Deferred ablation 43.7 (13.6) 45.8 (13.3) 45.1 (13.1) 47.1 (12.7)
Difference (95% CI)a –1.4 (–3.8 to 1.0) 0 (–2.7 to 2.7) 1.4 (–1.3 to 4.1) –1.9 (–4.5 to 0.8)
SF-36 mental health score, mean (SD)
Early ablation 49.2 (10.3) 50.4 (10.5) 51.2 (10.1) 50.5 (10.2)
Deferred ablation 49.3 (10.7) 49.0 (10.8) 49.4 (10.5) 50.2 (10.6)
Difference (95% CI)a –0.2 (–2.1 to 1.8) 1.4 (–0.7 to 3.4) 1.6 (–0.7 to 4.0) 0.1 (–1.9 to 2.2)
SF-36 physical component summary score, mean (SD)
Early ablation 38.5 (10.0) 40.4 (10.4) 41.8 (11.4) 42.6 (11.8)
Deferred ablation 38.8 (10.7) 39.6 (11.5) 40.8 (12.1) 41.2 (12.2)
Difference (95% CI)a –0.8 (–2.7 to 1.2) 0.2 (–1.8 to 2.2) 0.4 (–1.9 to 2.7) 1.0 (–1.1 to 3.1)
SF-36 mental component summary score, mean (SD)
Early ablation 49.2 (10.8) 51 (10.4) 51.7 (10.2) 50.9 (10.2)
Deferred ablation 49.4 (11.5) 50 (11.1) 50.1 (10.4) 51.5 (10.4)
Difference (95% CI)a –0.2 (–2.2 to 1.7) 0.9 (–1.2 to 3.1) 1.5 (–0.8 to 3.8) –0.7 (–2.8 to 1.4)
a Difference between two groups estimated by mixed model, adjusting for time, age, ulcer size and duration as a fixed
effect and trial centre and participant as a random effect. Deferred-ablation group as reference. The 95% CIs have not
been adjusted for multiplicity.
b EQ-5D index calculated using the value set for England.57
Notes
Data presented as mean (SD). Widths of the CIs have not been adjusted for multiplicity and should not be used for formal
inference. Missing scores were imputed using chained equation.
Reproduced from The New England Journal of Medicine, Gohel et al.57 A randomized trial of early endovenous ablation in
venous ulceration, vol. 378, pp. 2105–14. Copyright © 2018 Massachusetts Medical Society. Reprinted with permission.
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Safety data
Table 18 summarises the ablation procedures received by trial participants in the early and deferred groups
during 1 year of follow-up (AEs are shown). In the early-ablation group, 218 participants underwent at
least one ablation treatment (97.3%), whereas in the deferred group 171 participants did so (75.7%).
Table 19 summarises the procedural complications after endovenous ablation. The most common
complications were DVT and pain post ablation. The vast majority of DVTs were in crural veins and were
asymptomatic.
Table 20 shows the summary of SAEs. The number of SAEs possibly, probably or definitely related to the
ablation procedures was three in the deferred-ablation group and four in the early-ablation group, and all
were expected. SAEs assessed as being related are categorised in Table 21.
Baseline
Time of visit
Week 6
Treatment
Deferred
Early
5
0
10V
C
SS
 s
co
re 15
20
25
FIGURE 11 Summary of VCSS score in early- and deferred-ablation groups: VCSS score at baseline and 6 weeks
after randomisation.
TABLE 17 Summary of clinical success at 6 weeks after randomisation
Variable
Treatment group
p-valueEarly (N= 224) Deferred (N= 226)
VCSS total score, mean (SD)
Baseline 15.8 (3.3), n = 223 15.7 (3.1), n = 226
Week 6 10.5 (4.7), n = 218 12.6 (4.4), n = 210 < 0.001a
Clinical classification downgrade (C6 to C5), n (%)
Yes 106 (47.3) 72 (31.9) 0.001b
No 112 (50.0) 139 (61.5)
Missing 6 (2.7) 15 (6.6)
a p-value for t-test.
b p-value for Pearson’s chi-squared test.
Reproduced from The New England Journal of Medicine, Gohel et al.57 A randomized trial of early endovenous ablation in
venous ulceration, vol. 378, pp. 2105–14. Copyright © 2018 Massachusetts Medical Society. Reprinted with permission.
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TABLE 18 Summary of AEs
Variable Early (N= 224) Deferred (N= 226)
Total number of procedures 269 203
Total number (%) of participants having a procedure 218 (97.3) 171 (75.7)
Number (%) of surgical procedures
One 173 (79.4) 147 (86.0)
Two 39 (17.9) 17 (9.9)
Three 6 (2.8) 6 (3.5)
Four 0 (0) 1 (0.6)
Total number of AEs 117 130
Total number (%) of participants with an AE 67 (29.9) 83 (36.7)
Description of AE, n (%)
Systemic 7 (6.0) 6 (4.6)
Local 110 (94.2) 124 (95.4)
Outcome, n (%)
Recovered 111 (94.9) 111 (85.4)
Not yet recovered 6 (5.1) 19 (14.6)
Death 0 (0) 0 (0)
Unknown 0 (0) 0 (0)
Missing 0 (0) 0 (0)
TABLE 19 Summary of complications after endovenous ablation
Complication Early (N= 28) Deferred (N= 24)
Allergic reaction requiring local or no treatment 5 3
Bleeding requiring intervention 2 1
Cough/chest tightness 0 1
DVT 9a 3b
Infectionc 3 5
Oedema 1 0
Pain 6d 6
Participant-reported paraesthesia 1 1
Superficial thrombophlebitis 1 4
a Post-ablation DVT in the early-ablation group: calf vein thrombosis occurred in six participants, in four of whom the
thrombosis was identified on routine post-UGFS duplex ultrasonography scanning performed 7 days post UGFS (as this
was the local scanning regimen in one of the recruiting centres); endothermal heat induced thrombosis (non-occlusive)
occurred in three paraticipants.
b Post-ablation DVT: calf vein thrombosis (n = 3).
c Occurred in the perioperative period.
d Deemed severe in one participant.
Reproduced from The New England Journal of Medicine, Gohel et al.57 A randomized trial of early endovenous ablation in
venous ulceration, vol. 378, pp. 2105–14. Copyright © 2018 Massachusetts Medical Society. Reprinted with permission.
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TABLE 20 Summary of SAEs
Variable Early (N= 224) Deferred (N= 226)
Number (%) of participants undergoing an ablation procedure 218 (97.3) 171 (75.7)
Total number of procedures 269 203
Total number of SAEs 43 55
Number (%) of participants with SAE 30 (13.4) 35 (15.5)
Serious reason, n (%)
Death 3 (7.0) 4 (7.3)
Life-threatening 0 (0) 0 (0)
Persistently disabling 0 (0) 0 (0)
Hospitalisation required 38 (88.4) 50 (90.9)
Congenital abnormality 0 (0) 0 (0)
Other 2 (4.7) 1 (1.8)
Frequency, n (%)
Single episode 32 (74.4) 49 (89.1)
Intermittent 1 (2.3) 1 (1.8)
Frequent 1 (2.3) 0 (0)
Continuous 7 (16.3) 5 (9.1)
Unknown 2 (4.7) 0 (0)
Severity, n (%)
Mild 3 (7.0) 4 (7.3)
Moderate 17 (39.5) 23 (41.8)
Severe 18 (41.9) 20 (36.4)
Life-threatening or disabling 5 (11.6) 8 (14.6)
Relation to procedure, n (%)
Not related 38 (88.4) 51 (92.7)
Unlikely 1 (2.3) 1 (1.8)
Possibly 1 (2.3) 3 (5.5)
Probably 1 (2.3) 0 (0)
Definite 2 (4.7) 0 (0)
Outcome, n (%)
Recovered 36 (83.7) 46 (83.6)
Not yet recovered 1 (2.3) 1 (1.8)
Death 6 (14.0) 8 (14.6)
Unknown 0 (0) 0 (0)
Expectedness, n (%)a
Expected 4 (100) 3 (100)
a Expectedness is reported for all SAEs that are possibly, probably or definitely related to procedure (n = 7).
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Protocol deviations
There were 89 and 74 protocol deviations in early- and deferred-ablation groups, respectively. Table 22
shows the summary of the protocol deviations. The number of protocol deviations related to trial
treatment was 38 (involving 32 participants) in the early-ablation group and 32 (involving 31 participants)
in the deferred-ablation group. Participants with protocol deviations related to treatment were excluded
from the per-protocol analysis.
Sensitivity analysis
The per-protocol analyses included 387 participants after excluding those with protocol deviation related
to treatment. Figure 12 shows the KM curve based on the per-protocol analysis. The difference between
the two groups is less pronounced than in the ITT analysis as the participants with protocol deviations in
the deferred group experienced particularly poor healing (Figure 13). The smaller difference between the
TABLE 21 Medical Dictionary for Regulatory Activities (version 20.0) coding of the expected and related SAEs
Treatment
allocation System organ classes term Preferred term Lowest-level term
Early Musculoskeletal and connective tissue disorders Pain in extremity Leg pain
Early Surgical and medical procedures Vascular compression
therapy
Compression dressing
application
Early General disorders and administration site conditions Peripheral swelling Swelling of legs
Early Skin and subcutaneous tissue disorders Skin ulcer Leg ulcer
Deferred Injury, poisoning and procedural complications Laceration Laceration of head
Deferred Infections and infestations Urinary tract infection Urinary tract infection
Deferred Infections and infestations Infected skin ulcer Infected skin ulcer
TABLE 22 Summary of protocol deviations
Variable Early (N= 89a) Deferred (N= 74a)
Number of participants with a protocol deviation 59 58
Deferred ablation in early group, n (%) 17 (19.1) 0 (0)
Non-concordance with bandaging, n (%) 9 (10.1) 12 (16.0)
Early ablation in deferred group, n (%) 0 (0) 16 (21.3)
Other, n (%) 63 (70.8) 46 (62.2)
Follow-up visit missing/late 40 (63.5) 34 (73.9)
Photograph/tracing not taken 4 (6.4) 4 (8.7)
Incorrect consent initially completed 3 (4.8) 4 (8.7)
Ineligible 2 (3.2) 4 (8.7)
Other 14b (22.2) 0 (0)
a Number of protocol deviations; a participant may have more than one protocol deviation.
b Abnormal scan (n = 1); deferred reporting of healing (n = 1); ablation not completed for technical reason (n = 1);
one ablation outside 2 weeks (n = 4); no ablation (n = 5); other (n = 2).
Reproduced from The New England Journal of Medicine, Gohel et al.57 A randomized trial of early endovenous ablation in
venous ulceration, vol. 378, pp. 2105–14. Copyright © 2018 Massachusetts Medical Society. Reprinted with permission.
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treatment groups in Table 23 also illustrates that the participants in the deferred group who did not have
a protocol deviation had less severe ulcers. The 24-week ulcer healing rate in the deferred group was
76.3% in the ITT analysis and 82.6% in the per-protocol analysis. After adjusting for covariates in the Cox
regression, in the per-protocol analysis the HR for time to healing associated with early compared with
deferred ablation is 1.31 (95% CI 1.06 to 1.63; p = 0.01) (Table 24). In summary, although the deferred-
intervention participants in the per-protocol analysis had less severe ulcers, it was still observed that early
ablation led to more rapid ulcer healing in the per-protocol analysis.
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FIGURE 13 Kaplan–Meier curve showing ulcer healing time in the early- and deferred-ablation groups among
participants with protocol deviations (p< 0.001).
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FIGURE 12 Per-protocol analysis (excluding participants with a protocol deviation) KM curve showing ulcer healing
in the early and deferred (standard) ablation groups (p= 0.04).
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TABLE 24 Per-protocol analysis for time to ulcer healing (Cox regression model)
Variable Na na
Univariable modelb Multivariable modelc
HR (95% CI) p-value HR (95% CI) p-value
Treatment group
Deferred 195 170 Reference Reference
Early 192 180 1.25 (1.01 to 1.55) 0.04 1.31 (1.06 to 1.63) 0.01
Age (years) 387 350 0.99 (0.98 to 1.00) 0.02 1.00 (0.99 to 1.01) 0.56
Ulcer duration (months)
First quartile (0.9–2.2) 101 91 Reference Reference
Second quartile (2.3–3.1) 101 92 1.02 (0.76 to 1.37) 0.88 1.03 (0.77 to 1.39) 0.83
Third quartile (3.1–4.2) 96 91 1.09 (0.81 to 1.46) 0.56 1.14 (0.85 to 1.53) 0.38
Fourth quartile (4.2–8.4) 89 76 0.74 (0.54 to 1.00) 0.05 0.84 (0.61 to 1.15) 0.27
Ulcer size (cm2)
First quartile (0.4–1.5) 98 94 Reference Reference
Second quartile (1.6–2.9) 96 93 0.80 (0.60 to 1.07) 0.13 0.76 (0.57 to 1.03) 0.07
Third quartile (3–7.5) 98 88 0.50 (0.37 to 0.67) < 0.001 0.50 (0.37 to 0.67) < 0.001
Fourth quartile (8–235) 95 75 0.30 (0.22 to 0.40) < 0.001 0.29 (0.21 to 0.41) < 0.001
a N, total number of participants; n, number of participants with healing ulcer.
b Adjusted by centre as fixed effects.
c Adjusted by centre, age, ulcer size and duration as fixed effects.
TABLE 23 Per-protocol analysis for 12- and 24-week ulcer healing rate and ulcer-free time
Variable Early (N= 192) Deferred (N= 195)
Ulcer healing rate (95% CI) (%)a
12 weeks 63.9% (57.1% to 70.6%) 57.0% (50.2% to 64.1%)
24 weeks 86.4% (81.1% to 90.8%) 82.6% (76.8% to 87.6%)
Number (%) of participants with healed ulcer at 1 year 180 (93.8) 170 (87.2)
Number (%) of participants with recurrent ulcerb 23 (12.8) 28 (16.5)
Ulcer-free time (days), median (IQR) 309 (240–329), n = 177 286 (213–325), n = 176
a Data presented as estimation by KM curve (95% CI).
b The proportion reported among participants with ulcer healed at 12 months.
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Chapter 4 Economic evaluation results
Resource use and total cost analysis
Figure 14 and Appendix 9 show initial ablation procedures and overall subsequent resource use in the
450 randomised participants. Total mean cost per patient was calculated over 1 year. Participants who
withdrew from the trial before 12 months were not included in the cost analysis. Participants who died
during the year were included in the cost analysis, with costs set to £0 after the date of death. Hence, for
the purposes of the total cost analysis, 211 participants in the deferred-ablation group (226 randomised
minus 15 withdrawals, i.e. lost to follow-up or protocol deviations) and 208 participants in the early-
ablation group (224 randomised minus 16 withdrawals, i.e. lost to follow-up or protocol deviations)
completed 12 months of the trial or died (see Figure 3).
The total mean cost over 1 year was very similar in the two trial groups: £2514 (SD £2770) in participants
randomised to early ablation and £2516 (SD £3242) in the deferred-ablation group.
The early-ablation group incurred a greater initial cost due to the allocated ablation procedure, even
though the trial protocol suggested that participants in the deferred group should have an ablation
procedure once the ulcer was healed. Reasons for non-ablation in participants randomised to deferred
ablation are unclear, but both participant and clinician preferences are likely to have played a role. The
greater initial costs in the early-ablation group were compensated for by the lower costs of district nurse
visits and consumables to quicker wound healing. Other resource use was similar in the two groups.
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FIGURE 14 NHS and Personal Social Services costs (£) of early vs. deferred strategies over 1 year, n= 208 (early-ablation
group) and n= 211 (deferred-ablation group). Reproduced with permission from Cost-effectiveness analysis of a
randomized clinical trial of early versus deferred endovenous ablation of superficial venous reflux in patients with
venous ulceration. Epstein et al.71 British Journal of Surgery, vol. 106, © 2019 BJS Society Ltd Published by JohnWiley &
Sons Ltd.
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Table 10 shows the number of index endovenous ablation procedures performed. The trial also recorded
further interventions in the treatment visit CRF and in the monthly telephone follow-up. These may
include, for example, reinterventions for return of symptoms. Some of these may be non-protocol ablations
(e.g. ablation in the non-trial leg), but there is insufficient information to be certain.
Table 25 shows the total number of vein procedures recorded in the trial, including those reported in
the monthly telephone follow-up. To avoid double-counting, a record was assumed to be duplicated if
a participant reported a vein procedure in the same month both on the CRF and during the telephone
follow-up.
Cost-effectiveness analysis
The cost-effectiveness analysis uses data on both total costs and QALYs over 1 year. A total of 344 (76%)
of 450 participants were included in the complete-case cost-effectiveness analysis. Table 26 summarises
the pattern of missing data. Thirty-one (7%) participants had missing data for costs (because either they
withdrew from the trial or there was a protocol deviation). A greater proportion (16%) had some missing
data at 12 months for EQ-5D-5L. This arose because of withdrawal and because not all participants fully
completed all the questions in the HRQoL questionnaires at each follow-up. Overall, 24% had some
missing EQ-5D or cost data over the year.
TABLE 26 Pattern of missing data
Variable Early Deferred Total
Randomised, n 224 226 450
Any missing cost data over the year, n (%) 16 (7) 15 (7) 31 (7)
Missing EQ-5D-5L at baseline, n (%) 2 (< 1) 0 (0) 2 (< 1)
Missing EQ-5D-5L at 6 weeks, n (%) 13 (6) 18 (8) 31 (7)
Missing EQ-5D-5L at 6 months, n (%) 36 (16) 31 (14) 67 (14)
Missing EQ-5D-5L at 12 months, n (%) 36 (16) 36 (16) 72 (16)
Any missing data over the year, n (%) 51 (23) 55 (24) 106 (24)
Complete cases, n 173 171 344
TABLE 25 All varicose vein ablation procedures recorded in the triala
Number of ablation procedures per patient Early (N= 224) Deferred (N= 226)
No procedure 6 55
1 150 120
2 30 30
3 32 14
4 6 6
5 0 1
a Includes index interventions and reinterventions. Some procedures may include interventions on the non-trial leg.
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Table 27 shows the results of the cost and QALY regressions for the cost-effectiveness analysis.
In the complete-case analysis (model 1), the difference in cost was £163 (SE £318), the difference in QALYs
gained at 1 year was 0.041 (SE 0.017) and the ICER was £3976 per QALY. There was an 89% probability
that early venous surgery is cost-effective at the current willingness-to-pay (WTP) threshold of £20,000 per
QALY (Figure 15). Assuming bivariate normality to estimate SEs gave very similar results (model 2). There
was a significant negative correlation between costs and QALYs, indicating that participants with a worse
quality of life were also those who tended to incur greater health-care costs (correlation –0.294; p < 0.001).
In model 3, missing data were imputed. The mean difference in total cost was –£72 (SE £290, i.e. early
intervention was cheaper at 1 year), and the mean difference in QALYs gained over 1 year was 0.058
(SE 0.018). There was a 99% probability of early intervention being cost-effective at a threshold of
£20,000 per QALY.
Using alternative tariff values for the EQ-5D-5L resulted in a slightly smaller difference in QALY between
the treatment groups, but the ICER was similar to the base case (model 4).
The per-protocol analysis used the same approach as model 1, but excluded patients with protocol
deviations. Protocol deviations were seen in 117 patients (59 and 58 in the early and deferred groups,
respectively), of whom 71 had complete data. This left 273 patients for analysis (344 with complete data
at 12 months minus 71 protocol deviations). The ICER in this model was £8679 per QALY (model 5).
TABLE 27 Regression results for cost-effectiveness analysis
Model 1
(base case) Model 2 Model 3 Model 4 Model 5
Description of
model
Complete case
(n = 344), with
bootstrap SEs
(1000 samples)
and crosswalk
EQ-5D tariff63
Complete case
(n = 344), with
bivariate normal
SEs and crosswalk
EQ-5D tariff
10 multiple imputations
(n = 450), with bivariate
normal SEs and
crosswalk EQ-5D tariff
Complete case
(n = 344) with
bootstrap SEs and
Devlin EQ-5D-5L
tariff57
Per-protocol
compliers
(n = 273) with
bootstrap SEs
Difference in cost:
mean (SE), p-value
163 (318), 0.607 163 (322), 0.612 –72 (290), 0.803 163 (322), 0.612 486 (326), 0.137
Difference in
QALY: mean (SE),
p-value
0.041 (0.017),
0.017
0.041 (0.018),
0.024
0.058 (0.018),
0.002
0.033 (0.016),
0.039
0.056 (0.019),
0.003
ICER £3976/QALY £3976/QALY n/ca £4939/QALY £8679/QALY
n/c, not computable.
a ICER is not computable as early intervention is estimated to cost less and deliver greater QALY gain than
deferred intervention.
Note
Estimated correlation of residuals between cost and QALY in the bivariate normal model –0.294; p < 0.001.
Reproduced with permission from Cost-effectiveness analysis of a randomized clinical trial of early versus deferred
endovenous ablation of superficial venous reflux in patients with venous ulceration. Epstein et al.71 British Journal of
Surgery, vol. 106, © 2019 BJS Society Ltd Published by John Wiley & Sons Ltd.
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FIGURE 15 Cost-effectiveness acceptability curves for each model. Model 1: complete case (dashed line); Model 2:
complete case using bivariate normal model; Model 3: multiple imputation; Model 4: alternative EQ-5D-5L tariff;
Model 5: Per-protocol. Reproduced with permission from Cost-effectiveness analysis of a randomized clinical trial
of early versus deferred endovenous ablation of superficial venous reflux in patients with venous ulceration.
Epstein et al.71 British Journal of Surgery, vol. 106, © 2019 BJS Society Ltd Published by John Wiley & Sons Ltd.
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Chapter 5 Discussion
Interpretation
The EVRA trial is the first multicentre RCT to assess the effect of early endovenous ablation for superficial
venous reflux on ulcer healing in participants with venous ulceration. As standard care in the UK does not
usually involve venous surgery (and, if surgery is performed, it is generally deferred until after ulcer healing
with compression therapy), the results should be of interest to patients, clinicians and policy-makers.
The trial showed that early ablation of superficial reflux in addition to compression therapy significantly
accelerates ulcer healing. Participants randomised to the early-ablation group also benefited from more
ulcer-free time over the 12 months post randomisation.
Venous guidelines, worldwide,40,45 recommend the ablation of superficial venous reflux based on the
results of the ESCHAR trial, which demonstrated that superficial venous surgery reduced ulcer recurrence
compared with compression therapy alone.9,15 ESCHAR, however, did not show a benefit in terms of
ulcer healing, which may explain why leg ulcer care pathways usually do not include provisions for early
assessment and treatment of superficial reflux. The exception is the US Society for Vascular Surgery and
the American Venous Forum Guidelines, which make a weak recommendation (grade 2, level C) for
endovenous ablation in active ulceration based on the results of some cohort studies.45 In addition, the
lack of standardised leg ulcer pathways and the involvement of a range of specialists may contribute to
the inconsistent care delivered.8,41,44
It is interesting to note that the healing rates at 12 and 24 weeks achieved in the deferred-ablation group
(51.6% and 76.3%, respectively) are higher than those previously reported in the literature and seen in the
general venous leg ulcer population.72 This is likely to be as a result of good-quality compression applied
by the specialised, highly trained research staff and not representative of usual care (which varies across
regions and can suffer from lack of staffing and resource).44,73
Despite the excellent healing rates in the deferred-ablation group in this trial, participants randomised to
early ablation still demonstrated a shorter time to healing. A widespread strategy of early ablation is likely
to show an even greater benefit, as endovenous interventions are usually delivered as a single treatment
episode, in contrast with compression therapy, which requires ongoing compliance for optimal outcomes.
Implementation of early endovenous ablation for patients with venous leg ulceration will require considerable
changes to current care pathways and treatment paradigms. The EVRA trial results reinforce the NICE
recommendation that patients with leg ulceration not healed within 2 weeks should be referred promptly to
a vascular service for evaluation and treatment of venous disease.
Although the results of the subgroup analysis should be interpreted with caution, there is a clear trend
for a greater benefit from early ablation as ulcer duration increases. The inclusion criteria for the trial
stipulated an upper limit of 6 months in duration for ulcers. This was to minimise heterogeneity within the
trial population, but also because investigators expressed concerns about withholding endovenous ablation
from patients with ulcers that had failed to respond to 6 months of compression therapy. Whether or not
an even greater benefit would exist in those with an ulcer duration of > 6 months remains unclear.
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Adverse events
The most common complications of endovenous ablation were pain and DVT. The DVT rate seen in the
early-ablation group was high compared with other literature. However, in six of the participants DVT
was infrapopliteal, and in four of these the thrombosis was identified on routine post-UGFS duplex
ultrasonography performed 7 days post ablation (as per the local scanning regimen in one of the recruiting
centres). Therefore, it is likely that this represents a very high level of detection of subclinical DVT.
Although 98 SAEs were reported over the course of the trial, as may be expected given the age of the
trial population, only seven were deemed to be possibly, probably or definitely related to the ablation
procedures.
Health-related quality of life
Early ablation led to significant improvements in disease-specific (AVVQ) and general HRQoL (EQ-5D index
value) and body pain (SF-36 body pain), over the follow-up period. Differences were most pronounced at
6 weeks and 6 months post randomisation, which is consistent with more rapid healing.
Costs and cost-effectiveness
The complete-case analysis shows little difference in total mean cost per patient over 1 year between
early and deferred ablation [mean difference £163 (SE £318); p = 0.607]. The greater initial mean cost of
the early-ablation strategy is mostly offset by the reduced cost of treating unhealed leg ulcers. There is,
however, a substantial and statistically significant QALY gain over 1 year, with a mean difference of
0.041 (SE 0.017) QALYs; p = 0.017. The ICER of early ablation at 1 year is, therefore, £3976 per QALY,
compared with deferred ablation, with a high probability (89%) that early ablation is more cost-effective
at conventional UK WTP thresholds (£20,000 per QALY). Sensitivity analyses using alternative statistical
models give qualitatively similar results.
The difference in HRQoL appears to narrow at 1 year. Further follow-up is required to understand whether
or not the gains from early ablation are maintained in the longer term. If early ablation results in lower
recurrence risk in addition to reducing the time to healing, then even greater cost-effectiveness may be
present over the lifetime of the patient.74
The economic analysis protocol envisaged a within-trial cost-effectiveness analysis at 1 year and a decision
model [for details, see the health economic plan on the project web page: www.journalslibrary.nihr.ac.uk/
programmes/hta/11129197/#/ (accessed 18 April 2019)]. The purpose of the decision model was to
extrapolate recurrence rates in order to assess whether or not early ablation might be cost-effective over
a patient’s lifetime. At 1 year, there were insufficient recurrence events to reliably compare early with
delayed ablation. Hence, the decision model results based on EVRA trial data will be reported when the
trial extension results become available in late 2019.
As it was not possible to construct an economic model incorporating recurrence rates based on EVRA
trial data at 1 year, an interim analysis was undertaken based on recurrence and healing rates obtained
from the literature.31 These studies compared early ablation (with surgery or endothermal techniques)
plus compression versus compression only. None of these studies compared early ablation with delayed
ablation; hence, they are not directly comparable with the strategies under comparison in the EVRA trial
and are therefore not described in detail in this report. Nevertheless, the analysis showed that even if early
ablation reduced the rate of recurrence only, and did not have an impact on healing, this strategy would
be very cost-effective over a patient’s lifetime.74
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Generalisability
The trial was designed to be as pragmatic as possible, with broad inclusion criteria and interventional
strategies guided by the treating clinicians. Participants were recruited from 20 centres across England and,
although the trial had only a 7% inclusion rate and screened > 6500 patients to randomise 450, the baseline
characteristics of the trial participants appear representative of the target population, when compared with
other leg ulcer studies.46,75,76 Of those screened but not randomised, who were excluded for not meeting the
eligibility criteria, the two largest groups were those who had their ulcer for > 6 months (1772/6105, 29%) and
those whose ulcer had healed by the time of randomisation (610/6105, 10%), largely as a result of delays in
referral from primary to secondary care. Those with ulcers already healed have been shown in the ESCHAR trial
to benefit from superficial venous intervention. Findings from the pre-planned subgroup analyses suggest that
those with an ulcer duration of > 6 months may also benefit from early endovenous ablation. The results from
the EVRA trial may therefore be more generalisable than initially apparent. Furthermore, as > 90% of those
in the early-ablation group were treated within 2 weeks and 79.4% of these participants required only one
procedure, implementation in a NHS setting seems highly feasible. Patient concordance is also likely to be
higher with early ablation than with compression alone, as treatment success is less dependent on ongoing
patient compliance.
Strengths of the EVRA trial
Sample size and loss to follow-up
The EVRA trial is the largest and only RCT, to our knowledge, to evaluate the effect of early endovenous
ablation of superficial venous reflux, and target sample size of 450 participants was achieved. An adequate
number of healing events occurred. Loss to follow-ups, withdrawals and deaths did not exceed our
estimated 10% of the total recruitment; therefore, the trial was powered effectively.
Missing data
Only 31 (7%) participants were lost to follow-up, withdrew or violated protocol during the 12 months of
the trial and we were able to ascertain the primary and secondary clinical end points for the majority of
participants. Missing data were mainly confined to patient-reported outcomes such as AVVQ and SF-36,
for which there was marked attrition over time. This was addressed in the analysis by performing sensitivity
analyses using imputed values. Findings based on multiple imputation were the same as for the complete-
case analysis.
For the cost-effectiveness analysis, 24% of participants had some missing data (for EQ-5D or costs
over 12 months). The base case used only participants with complete data and sensitivity analyses used
multiple imputation of missing data. Both methods gave qualitatively similar results, showing that the
difference in cost was not significantly different from zero, whereas early ablation was associated with a
substantial and significantly greater QALY gain.
Verification visit and blinded outcome assessment
Although the treatment allocation could not be blinded, it is believed that the blinded outcome assessment
is a key strength of the trial.
Limitations of the EVRA trial
Centre variation
Despite each centre having an established leg ulcer care pathway, variations of practice existed between
centres, most importantly in the choice of endovenous modality. In order to minimise these variations, we
stratified by centre and stipulated standardised ablation principles. Similarly, compression regimens varied
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across participants and for the same participant, who may have received multiple different compression
therapies. In general, a pragmatic approach was adopted.
Superficial venous reflux patterns
The patterns of superficial venous reflux and presence and extent of deep venous incompetence varied.
However, the results support previous studies that show clear benefits of treating superficial venous reflux,
even in the presence of concomitant deep-venous incompetence.46,77,78
Post-ablation duplex
The 6-week follow-up duplex ultrasonography was stipulated only in the early-ablation group, whereas the
deferred group strategy was as per standard care. This may have led to more repeat procedures and a
higher procedure success rate than in the deferred-ablation group; however, this is not relevant to the
primary outcome of time to ulcer healing.
Ulcer recurrence
The trial follow-up period was only to 1 year and hence was too short to give meaningful recurrence data,
as there is a potential bias against the early-ablation group. With ongoing follow-up and longer-term
recurrence data, we anticipate that this bias will diminish. The follow-up period for the extension is now
complete (as of 31 March 2019) and, at the time of publication, we are cleaning and locking the database
prior to data analysis. No new data available to date.
Endovenous modality
The clinicians were permitted to use modalities of their choice subject to some core stipulations of ablation.
Despite the trial showing an overall benefit for early ablation, there is no clear distinction of benefit between
the various endovenous modalities. The common modality used in this trial was ultrasonography-guided
sclerotherapy, most likely reflecting its low cost and versatility, although some large RCTs have shown
that complete venous occlusion may be lower with UGFS than with endovenous ablation.37,55 Longer-term
follow-up is ongoing and should help determine whether or not this will affect longer-term clinical outcomes
and recurrence rates.
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Chapter 6 Conclusion
Overall conclusions
Early endovenous ablation of superficial truncal reflux in addition to compression therapy accelerates the
healing of venous leg ulcers compared with deferred ablation.
Although there is little difference between early and deferred ablation for endovenous superficial venous
ablation in terms of the total mean cost per patient over 1 year, early ablation results in a significant gain
in QALYs compared with deferred ablation. Therefore, early ablation has a high probability of being
cost-effective at NICE WTP thresholds.
Implications for health care
Findings from this trial suggest that, for people with venous leg ulcers, early assessment and ablation of
superficial venous reflux, in addition to compression therapy, accelerates healing and produces health
economic benefits. Implementation of early assessment and endovenous ablation of superficial venous
reflux will require further development of care pathways between primary and secondary care.
Recommendations for research (numbered in order of priority)
1. Follow up patients for longer to determine if early endovenous ablation influences ulcer recurrence
rates in the medium and long term.
2. Evaluate the benefit of early ablation for superficial venous reflux in patients with venous leg ulceration
of > 6 months’ duration.
3. Determine the implications of deep-venous incompetence and occlusive, and the potential role of
deep-venous stenting to improve venous outflow of the limb.
4. Evaluate the optimal technique and the extent of eradication of superficial venous incompetence in
patients with venous ulceration.
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Appendix 1 Patient and public involvement
Introduction
In addition to the ethical obligation of researchers to include patients and the public in research, the
NIHR grant application process requires an element of public consultation from the outset. The benefits
of public involvement have been shown throughout all stages of research, including identifying outcome
measures.79,80 More recent systematic reviews of patient involvement in research highlighted that active
participation in research can lead to more relevant research by identifying patient-important outcomes and
more credible results.81,82
In order to avoid a tokenistic approach to PPI, the INVOLVE Briefing Notes for Researchers: Public
Involvement in NHS, Public Health and Social Care Research were consulted from the outset to plan PPI
involvement in the trial.83 The notes reinforce the importance of early engagement of lay members to
enhance inclusivity, ownership of the study and a sense of purpose.
How patient and public involvement influenced the research design
Patient consultation
The 2004 ESCHAR trial suffered from a high crossover rate, as 19% of patients randomised to surgery
refused an operation and this weakened the power of the trial.15 It was assumed that the less invasive
interventional modalities employed in the EVRA trial would not have the same rate of refusal. To corroborate
this assumption, a small group of patients with active leg ulceration were consulted with the proposed trial
design to see if they would be willing to undergo early intervention. Almost all the patients agreed that they
would have been willing to participate in the trial, as they all wished to undergo intervention to heal their
ulcer, and the trial offers the possibility of being treated sooner than standard care coupled with a less
invasive strategy than open surgery.
Patient collaboration
A patient with healed leg ulceration (Bruce Ley-Greaves) who had previously shown an interest in research
was approached to join as a lay member co-applicant to assist in the design of the research trial and
ensure that the research question and outcomes were relevant to those affected by venous leg ulceration.
Lay member involvement at the design stage helped the EVRA trial team gain insight into the following
(quotations from Bruce Ley-Greaves):
l patients’ fears and lack of knowledge about procedure and options
l thoughts on early referral and intervention (‘my ulcer would have healed quicker if I had been referred
and treated promptly as intervention had an immediate impact’)
l deciding an appropriate primary outcome measure (‘time to healing is the most important outcome as
the smell associated with the ulcer affected my social confidence’), as well as important secondary
outcome measures, including patient quality of life and ulcer-free time
l the frequency of follow-ups (‘most patients would benefit from a 6-week clinic visit and monthly
telephone calls to give them reassurance that they were not lost in the system as most patients are
discharged out into the community post procedure’).
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Role description and expectations
In line with INVOLVE guidance, a role description was drafted to detail the expectations, commitment
levels of the post, details of reimbursement for travel/time and some training and support resource links,
including a link to the INVOLVE jargon buster (see Appendix 10).84
The lay member co-applicant agreed to act as our trial-specific PPI representative for the duration of the trial
and join the TSC that met on an annual basis at a minimum. The trial manager and PPI representative met
several times on an informal basis throughout the trial. All out-of-pocket expenses were covered for travel to
the meeting and refreshments were provided at each meeting.
Trial set-up phase
As part of the set-up phase, the PPI representative reviewed all the patient-facing documents, including,
but not limited to, the patient information sheet, consent form and patient diaries prior to Research Ethics
Committee submission, to ensure that the language was appropriate and easily understood and that
jargon was eliminated. Feedback from sites during the recruiting phase indicated that this was a successful
exercise as patients needed little clarification after reading the patient information sheet.
Recruitment phase
The PPI representative attended the first TSC meeting and contributed and co-approved the charter.
During the recruitment phase, he was an active member of the committee and attended all the TSC
meetings, either in person or via teleconference, depending on availability.
To aid recruitment, he suggested that recruitment posters and leaflets were placed in GP surgeries
to help recruit patients from primary care and contributed to the design of these. The impact of the
recruitment posters and leaflets was difficult to evaluate; however, several patients who saw the posters
requested referral to the recruiting hospitals and subsequently participated in the trial.
The trial manager kept in regular contact with the PPI representative in between TSC meetings to keep
him engaged and informed of trial progress, particularly recruitment numbers. A shopping voucher was
offered as recognition for his time.
Follow-up phase
Trial participants were e-mailed a newsletter during the follow-up phase to keep them updated on trial
progress and timelines, and when they could expect to find out the results of the trial. The PPI representative
helped design this newsletter, which also included a one-page article on the PPI involvement within the trial.
Results
The PPI representative attended the TSC/DMC results meeting to help provide a public/patient perspective
on the interpretation of trial findings.
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Dissemination
The PPI representative contributed to the design of the dissemination plan to ensure that the research
team will disseminate the results to trial participants, the general public and health professionals, and has
contributed to and reviewed the plain English summary for this report.
Measuring the impact of the EVRA trial
As the HTA programme has granted an extension to the trial to collect recurrence data, there will be an
opportunity for the PPI representative to be involved in the adoption of the trial results in clinical practice
and measuring the impact of a trial’s findings and informing future trial design.
The EVRA trial team eagerly await the findings from the current University of Oxford study Patient and
Public Involvement Intervention to Enhance Recruitment and Retention in Surgical Trials (PIRRIST),85
which aims to determine if PPI can improve recruitment and retention in clinical trials.
Evaluating patient and public involvement
A PPI involvement feedback meeting was convened in August 2017 to obtain the PPI representative’s
views on his involvement to date. The results of this meeting are summarised in Table 28. Written consent
was obtained to use direct quotations.
Interestingly, these opinions are in line with results of the 2013 Evidence Base for Patient and Public
Involvement in Clinical Trials (EPIC) study,86 which concluded that involvement from patients and the
public is successful if the ‘goals are clear, if there are well developed plans for PPI in a trial, and if models
of PPI are more responsive and managerial (e.g. membership of a Trial Management Group) rather than
restricted to general oversight (e.g. membership of a TSC)’.
Summary
Based on the findings of the lay member involvement feedback, when designing future studies the
research team would aim to:
l involve more than one member from the outset (e.g. a patient representative, someone newly
diagnosed with the condition and a member of the public)
l include the members in the Trial Management Group discussions if appropriate
l ensure that the trial manager spends time with the members before and after meetings to explain
reports and debrief
l ensure that TSC meetings are always held face to face
l provide an additional study-specific ‘jargon buster’ dictionary
l ensure that the reimbursement schedule is clear at the outset and calculated in line with the INVOLVE
Policy on Payments and Expenses for Members of the Public87 advice, considering an hourly rate of
payment for time.
By incorporating these findings in future trial design, the EVRA trial team hopes to aid the INVOLVE vision:
by 2025 INVOLVE expect ‘all people using health and social care, and increasing numbers of the public,
to be aware of and choosing to contribute to research by identifying future research priorities and research
questions, informing the design and development of innovations, participating in research studies,
advocating for the adoption and implementation of research in the NHS’.88
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TABLE 28 Lay member involvement feedback (August 2017)
What he enjoyed the most What he would do differently
Education about leg ulcers:
Learning more about leg ulcers and their
treatment . . .
And:
. . . the chance to see better ways of doing something
More specific jargon buster, in addition to the INVOLVE
dictionary:
Some form of dictionary would help, as sometimes I sat
there thinking ‘what does this mean?’ but didn’t necessarily
want to jump in and say ‘sorry I don’t know what you’re
talking about’
. . . the jargon buster is more helpful than the PPI videos
as I did lose interest easily as they seemed to go on a bit
Repaying health-care providers:
Being able to [provide] feedback [on] treatment and
say thank you for previous care
Clearer reimbursement schedule, payment for time:
For the number of meetings payment was not necessary as
I was learning and I was paying back and giving back to the
system but if I was coming more often, though, there
should be some sort of payment, for example £30 to £50
Being able to offer insights into personal treatment
experiences, referral problems, social concerns of
having an leg ulcer:
Sitting at GP getting frustrated and down about
the whole thing, wondered what was going to
happen. I’m rotting away here
Include another representative for support and understanding:
Include a second person to gain a better understanding
on the basis that the two reps got together outside the
meeting to debrief with the Trial Manager. That would
be the advantage of having a second person
Seeing that his input made a difference:
I was pleased to contribute to the study design and
that my ideas, such as posters in the GP surgeries,
ideas [sic] were listened to
Participant documents were interesting to read
and I was pleased to help make items more
user friendly
Pre-TSC meeting to talk through the trial manager’s report and
an after-meeting debrief:
I had no problems with confidence speaking up but I
usually only say something when I think I have some to
contribute. I didn’t like to interrupt as I thought there was a
job to be done and everyone is on short timescales and
things did become clear late but a chance to speak before
and after the meeting to go over detail I did not understand
would be useful
Reimbursement for time and contribution:
. . . the thank you voucher was a lovely touch and
reinforced the collaboration
Ensure that all participants always attend in person as easier to
engage:
Better to have face-to-face meetings preference. Did not
feel like a burden to attend meetings and combine with
other things I wanted to do, like meet friends
. . . much hard to understand items when discussed over a
teleconference than in person
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Appendix 2 Trial committees’ meeting dates
Data Monitoring and Ethics Committee
l 21 October 2013.
l 30 June 2014.
l 22 April 2015.
l 15 January 2016.
l 26 July 2016.
l 17 January 2018.
Trial Steering Committee
l 12 December 2013.
l 24 April 2014.
l 5 November 2014.
l 19 October 2015.
l 23 June 2016.
l 4 May 2017.
l 17 January 2018.
Investigator meetings
l 25 April 2013.
l 20 June 2013.
l 27 November 2013.
l 24 April 2014.
l 28 November 2014.
l 25 May 2015.
l 11 November 2015.
l 8 July 2016.
l 11 July 2017.
l 28 February 2018.
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Appendix 3 Digital photograph protocol
Ulcer tracing
The ulcer size was determined at the baseline and 6-week clinic visit via manual tracing:
l Place planimetry (with 1 cm2 markers) grids over the wound.
l Trace around end of ulcer with an indelible pen.
l Count the square descriptive units (cm2) and enter into InForm.
l Scan tracing and save as PtTrialnumber_Baseline_tracing_dd/mm/yy.
l E-mail to EVRAtrial@imperial.ac.uk via the Imperial College FileExchange: https://icseclzt.cc.ic.ac.uk/.
Digital photograph of the ulcer
The ulcer size was determined at the baseline and 6-week clinic visit via digital photograph:
l A digital camera (minimum 8 megapixel) should be used (recommended trial camera is the Sony
Cyber-shot DSC-WX60 16.2 Megapixel Digital Camera).
l Write the patient trial ID on the 3-cm calibration strip (red and white strips found in the site file) and
place in the field of vision of camera on the leg but not obscuring wound edge.
l Enable flash (all other camera macros should be disabled, i.e. general mode).
l Position camera 15 cm from wound perpendicular to mid-point.
l Capture two images to ensure one suitable image for analysis.
l If wound cannot be captured in one single image, divide wound into two or more segments and
summate images.
l Save photo as PtTrialnumber_Baseline_Photo_dd/mm/yy.
l E-mail to EVRAtrial@imperial.ac.uk via the Imperial College FileExchange: https://icseclzt.cc.ic.ac.uk/.
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Appendix 4 The EVRA flow diagram
Potential participants
screened for eligibility
Baseline visit
Consent and randomisation
Clinical assessment
Photograph/tracing of ulcer
Quality-of-life questionnaire
Multilayer compression/
stockings alone
Multilayer compression/
stockings and EVRA
Verification visit
4-weekly photos of
the ulcerb
Endovenous ablation
of superficial reflux
(within 2 weeks)
Endovenous ablation
of superficial reflux
(once ulcer healed or
at 6 months)
6 weeks
Quality-of-life questionnaire
Assessments of ulcer healinga
Colour duplex ultrasonography
(EVRA group only)
6 months
Self-completed quality-of-life
questionnaire
Assessments of ulcer healinga
12 months
Self-completed quality-of-life
questionnaire
Assessments of ulcer healinga
FIGURE 16 Early Venous Reflux Ablation flow diagram. a, Assessments of ulcer healing will be ongoing throughout
the trial follow-up period and will be performed by community nursing teams and research staff (at least every
month); b, once the research team has been informed by the patient that the ulcer has healed (can occur any time
during the 12 months).
DOI: 10.3310/hta23240 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 24
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Gohel et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
79

Appendix 5 Decision rules for verification of the
primary outcome measure
Verification of ulcer healing will be by clinical assessment and digital photography, to be repeatedweekly for 4 weeks. The digital images will be evaluated by two blinded expert assessors in order to
ascertain the date of healing, which will be considered the primary healing end point. Disagreements will
be resolved with involvement of a third blinded expert reviewer if necessary.
If the two blinded assessors agree that the reference ulcer has healed at the first photograph, the date of
healing notification (by patient or community nurse) will be taken as the date of ulcer healing. If the two
blinded assessors agree that the reference ulcer has healed at subsequent photographs, the date of those
photographs will be used as the date of healing. If the two blinded assessors agree that the reference ulcer
has healed at the first photograph, but the ulcer reoccurs at subsequent photographs, the date of healing
from the first photograph will be used and the reoccurrence will be noted in the electronic CRF. Patients
may undergo intervention for venous reflux after the first point the ulcer is confirmed healed (they do not
have to wait until all four photographs are verified).
If the two assessors say ‘unsure’, then the ulcer has not healed at that point and the next photograph will
be assessed.
If the two blinded assessors disagree on whether or not the reference ulcer has healed, there will be the
following combinations with regard to healing:
l Yes/unsure.
If the two assessors state ‘yes/unsure’ then the ulcer has healed, using the date provided by the
assessor who said ‘yes’ or if the first photograph, the date of healing notification will be used.
l No/unsure.
If the two assessors state ‘no/unsure’ then the ulcer has not healed.
l Yes/no.
If the two assessors state ‘yes/no’ a third assessor will be consulted and will decide if the ulcer is healed
or not. The third assessor’s decision will be final. If they are unsure whether or not the ulcer has healed,
the ulcer will be considered unhealed.
If no photographs of the reference ulcer are available, the unblinded date and the treating nurse/GP
recorded will be used if available.
If the (treating) nurses state that the wound is healed and stop taking photographs but blinded assessors
say that the wound is not healed, then the wound is considered healed.
If photographs are taken of a participant for > 12 months and the date of healing occurs beyond 12 months
post randomisation, then the participant will be regarded as unhealed at 12 months.
Photographs taken after a large interval of time has elapsed (i.e. ≥ 1 month) since the due date of the last
healed photograph (post-healed photograph 4), will not be included in the blinded outcome assessment.
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Appendix 6 Health economic unit costs
Resource Unit cost (£) Assumption Source
Index procedure
Staff procedure costs
EVLA 5.49/minute Assumed same cost/minute
for RFA
Brittenden et al. 201589
UGFS 4.67/minute Assumed same cost/minute
for MOCA
Brittenden et al. 201589
Disposable kit or catheter prices
EVLA 238.60 Angiodynamics (Caley Kitchen,
14 February 2018, personal
communication). List price catheter
£200. Generator £22,000 (assuming
2-year life, 600 procedures in total,
cost of capital 3.5% per year). This
gives an annuitised cost per procedure
of £38.60
RFA 543 Harriet Ellis, Imperial College Healthcare
NHS Trust, 16 November 2017,
personal communication. Includes
generator rental
MOCA 375 Harriet Ellis, personal communication
Other theatre consumables and anaesthetic
EVLA 66 Brittenden et al. 201589
RFA 66 Assumed same cost as EVLA
UGFS 50 Brittenden et al. 201589
MOCA 50 Assumed same cost as UGFS
Other costs of vein ablations (pre-procedure and recovery)
EVLA 72 Brittenden et al. 201589
RFA 72 Assumed same cost as EVLA
UGFS 42 Brittenden et al. 201589
MOCA 42 Assumed same cost as UGFS
Consumables ulcer healing
KTwo compression bandages 7.84 Assumed changed two
times per week until
healing
NHS supply chain90
VenoTrain® ulcertec
compression stockings
(Bauerfeind, London UK)
27.10 Assumed two pairs
changed every 3 months
until healing
NHS Supply Chain90
Ulcer dressing Assumed changed two
times per week until
healing
NA dressing 11.20 (for 40) NHS Supply Chain90
Inadine 9.5 × 9.5 cm 15 (for 25) NHS Supply Chain90
Atrauman® dressing (Paul
Hartmann Ltd., Heywood, UK)
10.89 (for 30) Assumed used if no other
information provided
NHS Supply Chain90
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Resource Unit cost (£) Assumption Source
Consumables after healing to prevent recurrence
Class 2 compression stocking 31.27 Assumed changed every
3 months
NHS Supply Chain90
Admissions to hospital (other than vein procedures)
Overnight stay without
procedure
265/night NHR Reference Costs 2015 to 2016.91
Excess bed-day: peripheral vascular
disorders with CC score 2–4
Spinal surgery 4142 Not ulcer related NHR Reference Costs 2015 to 2016.91
Elective inpatient
Shoulder replacement 5110 Not ulcer related NHR Reference Costs 2015 to 2016.91
Elective inpatient91
Ankle surgery 2667 Not ulcer related NHR Reference Costs 2015 to 2016.91
Elective inpatient
Hip replacement 5877 Not ulcer related NHR Reference Costs 2015 to 2016.91
Elective inpatient
Knee replacement 5745 Not ulcer related NHR Reference Costs 2015 to 2016.91
Elective inpatient
Cataract 917 Not ulcer related NHR Reference Costs 2015 to 2016.91
Elective inpatient
Hernia repair 1726 Not ulcer related NHR Reference Costs 2015 to 2016.91
Elective inpatient
Pacemaker 2063 Not ulcer related NHR Reference Costs 2015 to 2016.91
Elective inpatient
Angiography and stent 1449 Ulcer related NHR Reference Costs 2015 to 2016.91
Day case
Follow-up outpatient visit
Without procedure 140/visit NHR Reference Costs 2015 to 2016.91
Vascular surgery
Office-based sclerotherapy 245/visit Brittenden et al. 201589
Primary care
Visit to district nurse/general
practice nurse/vein clinic
38/visit Assume 15.5 minutes NHR Reference Costs 2015 to 201691
District nurse home visit 72/visit Includes travel time NHR Reference Costs 2015 to 201691
Visit to GP 36/visit PSSRU 201692
GP home visit 88/visit Includes travel time PSSRU 2015.93 Expenditure and unit
costs
Other health care use
Occupational therapist 79/visit NHR Reference Costs 2015 to 201691
Physiotherapist 49/visit NHR Reference Costs 2015 to 201691
Home carer visit 38/visit Nursing care Assume same as district nurse
Home help visit 29/visit Personal care NHS Digital.94 Expenditure and unit
costs
Medicines68
Apixiban 2.5 mg 4.40/day 5 mg BD every day
Aspirin 75 mg 0.03/day 75 mg OD every day
Clopidogrel 75 mg 0.06/day 75 mg OD every day
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Resource Unit cost (£) Assumption Source
Dalteparin 12,500 units/ml 20.32/day Males For average weight 96 kg,
18,000 units/day
14.12/day Females For average weight 80 kg,
12,500 units/day
Warfarin 0.04/day
Rivaroxaban 10mg 3.60/day 20 mg OD
Clexane (Enoxaparin) 11.02/day Male 1.5 mg/kg OD
7.84/day Female
Dabigatran 150 mg 1.70/day 150 mg BD
BD, twice daily; NA, non-adherent; OD, once daily; PSSRU, Personal Social Services Research Unit.
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Appendix 7 Recruitment per centre
EVRA site Participants recruited, n
Imperial College Healthcare NHS Trust 45
Cambridge University Hospitals NHS Foundation Trust 27
Worcestershire Acute Hospitals NHS Trust 20
North West London Hospitals NHS Trust 29
Gloucestershire Hospitals NHS Foundation Trust 124
Heart of England NHS Foundation Trust 51
University Hospitals Birmingham NHS Foundation Trust 9
North Cumbria University Hospitals NHS Trust 32
The Dudley Group NHS Foundation Trust 8
Royal Wolverhampton NHS Trust 3
York Teaching Hospital NHS Foundation Trust 2
Hull and East Yorkshire Hospitals NHS Trust 7
Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust 22
Frimley Health NHS Foundation Trust 6
University Hospitals Plymouth NHS Trust 23
Bradford Teaching Hospitals NHS Foundation Trust 6
Salisbury NHS Foundation Trust 5
Leeds Teaching Hospitals NHS Trust 4
Sheffield Teaching Hospitals NHS Foundation Trust 6
Taunton and Somerset NHS Foundation Trust 21
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Appendix 8 Recruitment graph
Monthly (actual)
Monthly (target)
Cumulative (actual)
Cumulative (target):
until October 2015
Cumulative (target):
post October 2015
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FIGURE 17 The EVRA trial recruitment graph (target vs. actual recruitment). Initial target recruitment was 24
participants a month, which was revised to 13 participants a month in October 2015. The target of 450 participants
was achieved in September 2016.
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Appendix 9 Total resource use
The following table shows the total resource use reported during the trial (n = 450), and mean (SD) costper participant with 1 year of follow-up (n = 419). Analyses without imputation.
Resource type
Resource use (total)
Early
(N= 208),
mean cost (£) SD (£)
Deferred
(N= 211),
mean cost (£) SD (£)
Early
(N= 224)
Deferred
(N= 226)
Treatment visits in the trial leg 523 368 370 369
Number of procedures 7 55
One or more procedure 217 171
Two or more procedures 45 24
Three or more procedures 6 7
Four procedures 0 1
Compression and dressings until healing
(cost)
229 230 255 242
Compression stockings after healing
(cost)
87 33 77 39
Hospital inpatient and day case
admissions, not recorded as trial
procedures
27 16 227 693 207 1526
Of which further ablation
procedures, not recorded as trial
procedures
12 5
Visits to district nurse 1947 2196 102 148 112 169
Visits from district nurse 624 1025 220 804 366 1263
Visits to GP 528 546 89 84 91 92
Visits from GP 23 49 9 28 20 56
Outpatient consultations and
procedures, not recorded as trial
procedures
807 731 588 851 527 952
Of which further ablation
procedures, not recorded as trial
procedures
73 69
Occupational therapy (visits) 6 14 2 17 5 24
Warfarin 1 4 2 4
Rivarox 16 106 24 159
Apixaban 13 114 1 9
Dalteparin 2 29 10 65
Dabigatran 0 4 2 36
Enoxaparin 0 0 2 23
Clopidogrel 1 3 1 3
Aspirin 2 4 2 4
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Resource type
Resource use (total)
Early
(N= 208),
mean cost (£) SD (£)
Deferred
(N= 211),
mean cost (£) SD (£)
Early
(N= 224)
Deferred
(N= 226)
Physiotherapy 106 247 25 109 57 285
Home care 1413 1573 257 1593 262 1207
Home help 875 882 121 799 121 646
Total cost 2514 2770 2516 3242
Hospital admissions unrelated to venous
leg ulcer
59 31 342 1435 192 1340
Outpatient visits unrelated to venous
leg ulcer
151 156 98 207 103 414
Out-of-pocket expenses 87 122
Unpaid carer (days) 4673 5132
Off-work days 921 1458
Normal days lost 4068 4947
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Appendix 10 Lay member role description
Role description of lay panel member for the 
EVRA Trial Steering Committee (TSC) 
For further details about this project – please contact the Trial Manager, Francine 
Heatley  
Role Description for:  
Bruce Ley-Greaves, lay member on Steering Group for the EVRA Research Project  
EVRA Study Summary: 
The EVRA study is for participants who have leg ulcers. A venous leg ulcer is a 
longstanding (chronic) wound on the leg or foot. These ulcers may either not heal or 
take a long time to heal and are usually caused by your leg veins not working very 
well. This problem with the veins is sometimes called varicose veins.  
The usual care for venous ulcers is compression bandaging, followed by treatment of 
the varicose veins once the ulcer has healed. This study is being done to find out 
whether early treatment (within 2 weeks) of the varicose veins by modern keyhole 
(endovenous) procedures, in addition to compression bandaging, will help the leg 
ulcer heal quicker compared to the treatment with compression bandaging alone. 
Studies have shown that treating varicose veins can reduce the chance of an ulcer 
coming back, but we do not know if treating the veins early (within 2 weeks) will help 
your ulcer heal quicker. 
Purpose of steering group: 
The role of the TSC is to provide advice, through its Chair, to research team on all 
appropriate aspects of the trial and in particular that the rights, safety and well-being 
of the trial participants are the most important considerations and should prevail over 
the interests of science and society.  
Other roles include: 
 monitoring the progress of the trial, adherence to the protocol, participant 
safety and the consideration of new information of relevance to the research 
question 
 to ensure appropriate ethical and other approvals are obtained in line with the 
project plan 
 to agree proposals for substantial protocol amendments and provide advice to 
the sponsor and funder regarding approvals of such amendments 
 to provide advice to the investigators on all aspects of the trial 
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The Imperial Research Team: 
The EVRA Chief Investigator is Professor Alun Davies. The trial manager is Francine 
Heatley.  
Professor Alun Davies: 
Professor Alun Davies Professor of Vascular Surgery at Imperial 
College London and a Consultant Surgeon whose NHS practice is 
based at Charing Cross and St Mary's Hospital, London. Professor 
Davies trained in Cambridge, Oxford, Plymouth, Boston (USA) and 
Bristol, prior to taking up a Consultant appointment in Charing 
Cross in 1994. Professor Davies is regarded as a world expert in the 
management of venous disorder. He has also written extensively on 
many aspects of vascular disease, writing over 370 peer reviewed 
manuscripts and runs a large research group. 
Francine Heatley, Trial Manager: 
Francine Heatley is a Trial Manager at the UKCRC registered 
Imperial Clinical Trials Unit (ICTU) in the School of Public Health 
within the Faculty of Medicine at Imperial College. She is a Biology 
graduate from the University of Nottingham and has over 10 years’ 
experience of conducting clinical research in therapeutic areas such 
as vascular surgery, cardiovascular and oncology. She spent 3 years 
working for an academic research organisation in Canada and is 
familiar in both Health Canada and FDA clinical trial regulations. 
Why involve you in the steering committee? 
We are inviting you to be a member of the EVRA as we believe public involvement is 
an essential part of the development of modern health and social care services. 
Research that reflects the needs and views of the public is more likely to produce 
results that can be used to improve health and social care.  
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The TSC Committee Members: 
The TSC chair:  
 Professor Julie Brittenden, Chair in Surgery (Clinical) 
Other committee members: 
 Miss Rebecca Jane Winterborn, Consultant Vascular Surgeon 
 Professor Andrea Nelson, Head of School and Professor of Wound Healing  
 Dr Richard Haynes, Research Fellow and Honorary Consultant Nephrologist 
 Dr Jane Warwick, Statistician, University of Warwick  
Other members who may attend the meetings: 
 Professor Alun Davies, Chief investigator 
 Francine Heatley, Trial Manager 
 ICTU Member, Operations Manager 
 Sponsor or HTA (funding) representative if requested 
 
Confidentiality:  
As a representative of the EVRA trial TSC you are asked not to share confidential 
information you may have received as a result of your position.  
Roles and responsibilities of user representative: 
We would like you to: 
 To attend the TSC meetings in person or by phone as per your preference 
 To represent the patient/lay user views of the EVRA Research Project at other 
meetings you are asked to attend.  
 To contribute to the discussion within the steering group and help us solve any 
problems we are facing with the study from your perspective. 
Essential Criteria:  
 Understanding or experience of the issues relating to chronic venous leg ulcers 
 Be able to maintain confidentiality  
 Have the time to attend meetings  
Desirable Criteria:  
It would be helpful if you have access to a computer and e-mail and have an 
understanding of the NHS and research processes 
Remuneration:  
Travel expenses and out-of-pocket expenses will be reimbursed and refreshments will 
be provided where appropriate.  
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Support:
You are able to access support and advice from the Trial manager (contact emails at
the top of this document). Please do not hesitate to ask you don’t understand
something, research is full of acronyms and sometimes we forget to say the terms in
full. Further information on Public involvement can be found here: 
NIHR HTA Information on lay member reps: http://www.nets.nihr.ac.uk/ppi
INVOLVE Information on public involvement in research: 
http://www.invo.org.uk/wp-content/uploads/2011/12/PIP1whatisitallabout.pdf and a 
helpful jargon buster http://www.invo.org.uk/wp-
content/uploads/2011/12/PIP44jargonbuster.pdf
Many thanks for contributing to the EVRA research trial we really do appreciate 
your involvement to help us improve the quality of
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